Note : Les descriptions sont présentées dans la langue officielle dans laquelle elles ont été soumises.
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
1 -(5-(2-CYANOPYRIDIN-4-YL)OXAZOLE-2-CARBONYL)-4-METHYLHEXAHYDROPYRROLO[3,4-
E]PYR
ROLE-5(1H)-CARBONITRILE AS USP30 INHIBITOR FOR USE IN THE TREATMENT OF
MITOCHONDRIAL DYSFUNCTION, CANCER AND FIBROSIS
FIELD OF THE INVENTION
The present invention relates to hexahydropyrrolo[3,4-b]pyrrole-5(1H)-
carbonitriles with activity as an
inhibitor of the deubiquitylating enzyme ubiquitin C-terminal hydrolase 30,
also known as ubiquitin
specific peptidase 30 (USP30), uses thereof, processes for the preparation
thereof and compositions
containing said inhibitor. This inhibitor has utility in a variety of
therapeutic areas, including conditions
involving mitochondrial dysfunction, cancer and fibrosis.
All documents cited or relied upon below are expressly incorporated herein by
reference.
BACKGROUND OF THE INVENTION
Ubiquitin is a small protein consisting of 76 amino acids that is important
for the regulation of protein
function in the cell. Ubiquitylation and deubiquitylation are enzymatically
mediated processes by which
ubiquitin is covalently bound or cleaved from a target protein by
deubiquitylating enzymes (DUBs), of
which there are approximately 100 DUBs in human cells, divided into sub-
families based on sequence
homology. The USP family are characterised by their common Cys and His boxes
which contain Cys
and His residues critical for their DUB activities. The ubiquitylation and
deubiquitylation processes
have been implicated in the regulation of many cellular functions including
cell cycle progression,
apoptosis, modification of cell surface receptors, regulation of DNA
transcription and DNA repair.
.. Thus, the ubiquitin system has been implicated in the pathogenesis of
numerous disease states including
inflammation, viral infection, metabolic dysfunction, CNS disorders, and
oncogenesis.
Ubiquitin is a master regulator of mitochondrial dynamics. Mitochondria are
dynamic organelles whose
biogenesis, fusion and fission events are regulated by the post-translational
regulation via ubiquitylation
of many key factors such as mitofusins. In humans, USP30 is a 517 amino acid
protein which is found
in the mitochondrial outer membrane (Nakamura et al, 2008, Mol Biol 19:1903-
11). It is the sole
deubiquitylating enzyme bearing a mitochondrial addressing signal and has been
shown to
deubiquitylate a number of mitochondrial proteins. It has been demonstrated
that USP30 opposes
parkin-mediated mitophagy and that reduction of USP30 activity can rescue
parkin-mediated defects in
mitophagy (Bingol et al, 2015, Nature 510:370-5; Gersch et al, 2017, Nat
Struct Mol Biol 24(11):
920-930; Cunningham et al, 2015, Nat Cell Biol 17(2): 160-169). USP30
inactivation can also increase
mitochondrial protein import, potentially through ubiquitylation of TOM
proteins (Jacoupy et al, 2019,
Sci Rep 9(1): 11829). A small proportion of USP30 has been localized to
peroxisomes, which are
generated through fusion of mitochondrial and ER vesicles, with USP30
potentially antagonizing the
Pex2/pexophagy pathway (Riccio et al, 2019, J Cell Biol 218(3): 798-807). The
E3 Ub ligase March5
and the deubiquitinase USP30 associate with the translocase and regulate
mitochondrial import, and
1
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
while March5 opposes mitochondrial import and directs degradation of
substrates, USP30
deubiquitinates substrates to promote their import (Phu et al, 2020, Molecular
Cell 77, 1107-1123).
Mitochondrial dysfunction can be defined as diminished mitochondrial content
(mitophagy or
mitochondrial biogenesis), as a decrease in mitochondrial activity and
oxidative phosphorylation, but
also as modulation of reactive oxygen species (ROS) generation. Hence a role
for mitochondrial
dysfunctions in a very large number of aging processes and pathologies.
For example, Parkinson's disease affects around 10 million people worldwide
(Parkinson's Disease
Foundation) and is characterised by the loss of dopaminergic neurons in the
substantia nigra. The exact
mechanisms underlying PD are unclear; however mitochondrial dysfunction is
increasingly appreciated
as a key determinant of dopaminergic neuronal susceptibility in PD and is a
feature of both familial and
sporadic disease, as well as in toxin-induced Parkinsonism. Parkin is one of a
number of proteins that
have been implicated with early onset PD. While most PD cases are linked to
defects in alpha-
synuclein, 10% of Parkinson's cases are linked to specific genetic defects,
one of which is in the
ubiquitin E3 ligase parkin. Parkin and the protein kinase PTEN-induced
putative kinase 1 (PINK1)
collaborate to ubiquitylate mitochondrial membrane proteins of damaged
mitochondria resulting in
mitophagy. Dysregulation of mitophagy results in increased oxidative stress,
which has been described
as a characteristic of PD. Inhibition of USP30 could therefore be a potential
strategy for the treatment
of PD. For example, PD patients with parkin mutations leading to reduced
activity could be
therapeutically compensated by inhibition of USP30.
It has been reported that depletion of USP30 enhances mitophagic clearance of
mitochondria and also
enhances parkin-induced cell death. USP30 has also been shown to regulate
BAX/BAK-dependent
apoptosis independently of parkin overexpression. Depletion of USP30
sensitises cancer cells to BH-3
mimetics such as ABT-737, without the need for parkin overexpression. Thus, an
anti-apoptotic role
has been demonstrated for USP30 and USP30 is therefore a potential target for
anti-cancer therapy.
The ubiquitin-proteasome system has gained interest as a target for the
treatment of cancer following
the approval of the proteasome inhibitor bortezomib (Velcade0) for the
treatment of multiple myeloma.
Extended treatment with bortezomib is limited by its associated toxicity and
drug resistance. However,
therapeutic strategies that target specific aspects of the ubiquitin-
proteasome pathway upstream of the
proteasome, such as DUBs, are predicted to be better tolerated (Bedford et al,
2011, Nature Rev
10:29-46).
Fibrotic diseases, including renal, hepatic and pulmonary fibrosis, are a
leading cause of morbidity and
mortality and can affect all tissues and organ systems. Fibrosis is considered
to be the result of acute
or chronic stress on the tissue or organ, characterized by extracellular
matrix deposition, reduction of
vascular/tubule/duct/airway patency and impairment of function ultimately
resulting in organ failure.
Many fibrotic conditions are promoted by lifestyle or environmental factors;
however, a proportion of
2
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
fibrotic conditions can be initiated through genetic triggers or indeed are
considered idiopathic
(i.e. without a known cause). Certain fibrotic disease, such as idiopathic
pulmonary fibrosis (IPF), can
be treated with non-specific kinase inhibitor (nintedanib) or drugs without a
well-characterized
mechanism of action (pirfenidone). Other treatments for organ fibrosis, such
as kidney or liver fibrosis,
alleviate pressure on the organ itself (e.g. beta blockers for cirrhosis,
angiotensin receptor blockers for
chronic kidney disease). Attention to lifestyle factors, such as glucose and
diet control, may also
influence the course and severity of disease.
Mitochondrial dysfunction has been implicated in a number of fibrotic
diseases, with oxidative stress
downstream of dysfunction being the key pathogenic mediator, alongside
decreased ATP production.
In preclinical models, disruption of the mitophagy pathway (through mutation
or knockout of either
parkin or PINK1) exacerbates lung fibrosis and kidney fibrosis, with evidence
of increased oxidative
stress.
Kurita et al, 2017, Respiratory Research 18:114, discloses that accumulation
of profibrotic
myofibroblasts is a crucial process for fibrotic remodelling in IPF. Recent
findings are said to show
participation of autophagy/mitophagy, part of the lysosomal degradation
machinery, in IPF
pathogenesis, and that mitophagy has been implicated in myofibroblast
differentiation through
regulating mitochondrial reactive oxygen species (ROS)-mediated platelet-
derived growth factor
receptor (PDGFR) activation. Kurita's results suggested that pirfenidone
induces PARK2-mediated
mitophagy and also inhibits lung fibrosis development in the setting of
insufficient mitophagy, which
may at least partly explain the anti-fibrotic mechanisms for IPF treatment.
Williams et al, 2015, Pharmacol Res. December; 102: 264-269, discuss the role
of PINK1-Parkin-
mediated autophagy in protecting against alcohol and acetaminophen-induced
liver injury by removing
damaged mitochondria via mitophagy. It is suggested that pharmacological
stabilization of USP8 or
inactivation of USP15 and USP30 may be potential therapeutic targets for
upregulating Parkin-induced
mitophagy and in turn protect against drug-induced liver injury. However, it
is noted that the DUBs
are regulated both transcriptionally and post-translationally, which may make
drug development for
targeting these specific enzymes challenging, and in addition, phosphorylated
ubiquitin was shown to
be resistant to DUBs. The authors conclude that upregulating PINK'
stabilization or kinase activity
may be a more effective target than inhibiting DUBs.
Williams et al, 2015, Biomolecules 5, 2619-2642, and Williams et al, 2015, Am
J Physiol Gastrointest
Liver Physiol 309: G324¨G340, review mechanisms involved in regulation of
mitochondrial
homeostasis in the liver and how these mechanisms may protect against alcohol-
induced liver disease.
Luciani et al, 2020, Nat. Commun. 11, 970, reports deregulation of
mitochondrial network in terminally
differentiated cells contributes to a broad spectrum of disorders, including
methylmalonic acidemia
(MMA). MMA is one of the most common inherited metabolic disorders, due to
deficiency of the
3
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
mitochondrial methylmalonyl-coenzyme A mutase (MMUT). MMUT deficiency induces
metabolic
and mitochondrial alterations that are exacerbated by anomalies in
PINK1/Parkin-mediated mitophagy,
causing the accumulation of dysfunctional mitochondria that trigger epithelial
stress and ultimately cell
damage. A link is suggested between primary MMUT deficiency, diseased
mitochondria, mitophagy
dysfunction and epithelial stress, and potential therapeutic perspectives for
MMA is provided.
Kluge et al, Bioorganic & Medicinal Chemistry Letters, 2018, 28 2655-2659,
reports that selective
inhibitors of USP30 accelerate mitophagy.
Series of derivatives of N-cyano-substituted heterocycles are disclosed as
deubiquitylating enzyme
inhibitors in PCT applications WO 2016/046530 (US 15/513125, US 15/894025, US
16/448066),
W02016/156816 (US 15/558632, US 16/297937, US 16/419558, US 16/419747, US
16/788446),
WO 2017/009650 (US 15/738900), WO 2017/093718 (US 15/776149), WO 2017/103614
(US 15/781615), W02017/149313 (US 16/078518),
W02017/109488 (US 16/060299),
W02017/141036 (US 16/070936), W02017/163078
(US 16/087515), W02017/158381
(US 16/080229), WO 2017/158388 (US 16/080506),
WO 2018/065768 (US 16/336685),
WO 2018/060742 (US 16/336202), WO 2018/060689 (US 16/334836), WO 2018/060691
(US 16/336363), WO 2018/220355 (US 16/615040),
WO 2018/234755 (US 16/615709),
WO 2020/212350, WO 2020/212351, WO 2021/043870, PCT/EP2021/059032
and
PCT/EP2021/064166, each of which are expressly incorporated herein by
reference. PCT application
WO 2019/171042 (US 16/977019), which is expressly incorporated herein by
reference, discloses the
use of N-cyanopyrrolidines as inhibitors of USP30 for the treatment of
fibrotic diseases.
Falgueyret et al, 2001, J.Med.Chem. 44, 94-104, and PCT application WO
01/77073 refer to
cyanopyrrolidines as inhibitors of Cathepsins K and L, with potential utility
in treating osteoporosis and
other bone-resorption related conditions.
PCT application WO 2015/179190 refers to
N-acylethanolamine hydrolysing acid amidase inhibitors, with potential utility
in treating ulcerative
colitis and Crohn's disease. PCT application WO 2013/030218 refers to
quinazolin-4-one compounds
as inhibitors of ubiquitin specific proteases, such as USP7, with potential
utility in treating cancer,
neurodegenerative diseases, inflammatory disorders and viral infections.
PCT applications
WO 2015/017502 and WO 2016/019237 refer to inhibitors of Bruton's tyrosine
kinase with potential
utility in treating disease such as autoimmune disease, inflammatory disease
and cancer.
PCT applications WO 2009/026197, WO 2009/129365, WO 2009/129370, and WO
2009/129371,
refer to cyanopyrrolidines as inhibitors of Cathepsin C with potential utility
in treating COPD. United
States patent application US 2008/0300268 refers to polyaromatic compounds as
inhibitors of tyrosine
kinase receptor PDGFR. PCT applications WO 2019/222468, WO 2019/071073, WO
2020/036940
and WO 2020/072964, Rusilowicz-Jones et al, 2020, bioRxiv 2020.04.16.044206
(20 April 2020), and
Tsefou et al, bioRxiv 2021.02.02.429344 (2 February 2021), refer to cyanamide-
containing compounds
4
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
as USP30 inhibitors. Yue et al, 2014, Cell Research, 24, 482-496, refers to a
diterpenoid derivative
15-oxospiramilactone as a USP30 inhibitor that induced mitochondrial fusion.
PCT application WO 2015/183987 refers to pharmaceutical compositions
comprising deubiquitinase
inhibitors and human serum albumin in methods of treating cancer, fibrosis, an
autoimmune disease or
condition, an inflammatory disease or condition, a neurodegenerative disease
or condition or an
infection. It is noted that deubiquitinases, including UCHL5/UCH37, USP4,
USP9X, USP11 and
USP15, are said to have been implicated in the regulation of the TGF-beta
signalling pathway, the
disruption of which gives rise to neurodegenerative and fibrotic diseases,
autoimmune dysfunction and
cancer.
PCT application WO 2006/067165 refers to a method for treating fibrotic
diseases using indolinone
kinase inhibitors. PCT application WO 2007/119214 refers to a method for
treating early stage
pulmonary fibrosis using an endothelin receptor antagonist. PCT application WO
2012/170290 refers
to a method for treating fibrotic diseases using THC acids. PCT application WO
2018/213150 refers
to sulfonamide USP30 inhibitors with potential utility in the treatment of
conditions involving
mitochondrial defects. Larson-Casey et al, 2016, Immunity 44, 582-596,
concerns macrophage Akt1
kinase-mediated mitophagy, apoptosis resistance and pulmonary fibrosis. Tang
et al, 2015, Kidney
Diseases 1, 71-79, reviews the potential role of mitophagy in renal
pathophysiology.
There exists a need for safe, alternative, and/or improved methods and
compositions for the treatment
or prevention of conditions involving mitochondrial dysfunction, cancer and
fibrosis, and the various
symptoms and conditions associated therewith. While not wishing to be bound by
any particular theory
or mechanism, it is believed that the compounds of the present invention act
to inhibit the enzyme
USP30, which in turn upregulates Parkin-induced mitophagy.
Acute Kidney Injury (AKI) is defined as an abrupt decrease in kidney function
occurring over 7 days
or less, with severity of injury staged based on increased serum creatinine
(SCr) and decreased urine
output as described in the Kidney Disease Improving Global Outcomes (KDIGO)
guidelines. AKI
occurs in about 13.3 million people per year, 85% of whom live in the
developing world and it is thought
to contribute to about 1.7 million deaths every year (Mehta et al, 2015,
Lancet 385(9987): 2616-2643).
AKI more than likely results in permanent kidney damage (i.e., chronic kidney
disease; CKD) and may
also result in damage to non-renal organs. AKI is a significant public health
concern particularly when
considering the absolute number of patients developing incident CKD,
progressive CKD, end-stage
renal disease and cardiovascular events. AKI has been found to be prevalent in
patients hospitalised by
COVID-19 and is strongly associated with hospital mortality, with
mitochondrial damage and
dysfunction reported as a potential pathophysiological mechanism and
therapeutic target (Kellum et al,
Nephrol Dial Transplant (2020) 35: 1652-1662).
5
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
AKI and CKD are viewed as a continuum on the same disease spectrum (Chawla et
al, 2017, Nat Rev
Nephrol 13(4): 241-257). Patients undergoing coronary artery bypass graft
(CABG) are at high risk for
kidney injury. There is an obvious unmet medical need in the development of
medicinal products for
the treatment and/or prevention of AKI.
The kidney is a site of high metabolic demand, with high mitophagy rates
demonstrated in vivo
(McWilliams et al, 2018, Cell Metab 27(2): 439-449 e435). Renal Proximal
Tubule Epithelial Cells
(RPTECs), a cell type with significant ATP requirement for solute/ion
exchange, are rich in
mitochondria and are the primary effector cells of Acute Kidney Injury (AKI)
in the kidney.
Mitochondrial dysfunction has been implicated in AKI/CKD mechanisms, both
through multiple lines
of evidence from preclinical AKI and CKD models and also through data
demonstrating abnormal
mitochondrial phenotypes in patient biopsies (Emma et al, 2016, Nat Rev
Nephrol 12(5): 267-280; Eirin
et al, 2017, Handb Exp Pharmacol 240: 229-250). Furthermore, Primary
mitochondrial disease often
manifest in renal symptoms, such as focal segmental glomerulosclerosis
(Kawakami et al, 2015, J Am
Soc Nephrol 26(5): 1040-1052) in patients with MELAS/MIDD, and also primary
tubular pathologies
in patients with Coenzyme Q deficiencies. Mutations in mtDNA can cause
maternally inherited
tubulointerstitial disease (Connor et al, 2017, PLoS Genet 13(3): e1006620).
Regarding mitochondrial quality control in renal injury (Tang et al, 2018,
Autophagy 14(5): 880-897)
demonstrated that renal injury was exacerbated following ischemic AKI in both
PINK1 KO and PARK2
KO mice, suggesting that PINK1/PARKIN-mediated mitophagy plays a protective
role following IRI
in the kidney. In addition, parkin/PINK1 mitophagy protects against cisplatin
induced kidney injury
(Wang et al, 2018, Cell Death Dis 9(11): 1113). Limited models of CKD are
available for mitophagy
investigation, supportive evidence for mitochondrial quality control in
fibrosis comes from studies on
fibrotic lung conditions such as COPD and IPF. Parkin knockout animals show
exacerbated lung
fibrosis in response to bleomycin (Kobayashi et al, 2016, J Immunol, 197:504-
516). Similarly, airway
epithelial cells from parkin knockout (KO) animals show exacerbated fibrotic
and senescent responses
to cigarette smoke (Araya et al, 2019, Autophagy 15(3): 510-526).
Preclinical models are available to study potential novel therapeutics,
through their ability to model
fibrosis pathology (e.g. collagen deposition) consistent with the human
condition. Preclinical models
can be toxin-mediated (e.g. bleomycin for lung and skin fibrosis), surgical
(e.g. ischemia/reperfusion
injury model and unilateral ureter obstruction model for acute
tubulointerstitial fibrosis), and genetic
(e.g. diabetic (db/db) mice for diabetic nephropathy). For example, both
examples previously given for
indicated IPF treatments (nintedanib and pirfenidone) show efficacy in the
bleomycin lung fibrosis
model.
6
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
Accordingly, there is a need for compounds that are inhibitors of USP30 for
the treatment or prevention
of conditions where inhibition of USP30 is indicated. In particular, there
exists a need for USP30
inhibitors that have suitable and/or improved properties in order to maximise
efficacy against the target
disease.
SUMMARY OF THE INVENTION
The present invention provides a compound of formula (I):
_---N
N ____________________________________________________ =N
N
CN CH3
or a pharmaceutically acceptable salt thereof.
The present invention is also directed to uses of the compound of formula (I),
particularly in the
treatment of conditions involving mitochondrial dysfunction, cancer and
fibrosis, and also processes
for the preparation thereof and pharmaceutical compositions containing said
compounds.
DETAILED DESCRIPTION OF THE INVENTION
The present invention is directed to USP30 inhibitors that have suitable
and/or improved properties in
order to maximise efficacy against the target disease. Such properties
include, for example, potency,
selectivity, physicochemical properties, ADME (absorption, distribution,
metabolism and excretion)
properties, including PK (pharmacokinetic) profile, and safety profile.
It is generally desirable to maximise the potency of a drug molecule against
the target enzyme in
relevant assays in order to lower the effective/efficacious dosage that is to
be administered to patients.
Compounds of the invention may be tested for USP30 affinity using the in vitro
biochemical
.. fluorescence polarization (FP) assay described herein.
USP30 is a transmembrane protein located in the outer membrane of
mitochondria, which are energy-
producing organelles present inside cells. Therefore, being able to
demonstrate cellular activity in vitro
is advantageous, as this is one of a number of components that may indicate a
greater ability to engage
the target in its physiological setting, i.e. where the USP30 inhibitor
compound is able to penetrate cells.
The USP30 cellular western blot (WB) assay aims to test the activity of
compounds against USP30 in
cells using an irreversible activity probe to monitor USP30 activity.
Analogously to the cellular western
blot assay, target engagement assessment (ex vivo) may be carried out in
either brain or kidney tissue
samples from compound-dosed animals.
7
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
To extend target binding knowledge to downstream pharmacodynamics, assessment
of TOM20 (an
outer mitochondrial membrane protein) ubiquitylation may be made.
In general, it is important for a drug to be as selective as possible for its
desired target enzyme; additional
activities give rise to the possibility of side effects. The exact
physiological role of many DUBs has yet
to be fully determined, however, irrespective of whatever role these DUBs may
or may not play, it is a
sound medicinal chemistry precept to ensure that any drug has selectivity over
related mechanistic
targets of unknown physiological function. Representative examples of DUB
enzymes for which the
compounds of the present invention may be screened against are UCHL1, UCHL3,
UCHL5, YOD1,
SENP2, SENP6, TRABID, BAP1, Cezanne, MINDY2/FAM63B, OTU1, OTUD3, OTUD5,
OTUD6A,
OTUD6B, OTUB1/UBCH5B, OTUB2, CYLD, VCPIP, AMSH-LP, JOSD1, JOSD2, USP1/UAF1,
USP2, USP4, USP5, USP6, USP7, USP8, USP9x, USP10, USP11, USP12/UAF1, USP13,
USP14,
USP15, USP16, USP19, USP20, USP21, USP22, USP24, USP25, USP28, USP32, USP34,
USP35,
USP36, USP45, USP46/UAF1, USP47 and USP48. Preferably, compounds of the
invention have good
selectivity for USP30 over one or more of these DUB enzymes.
Aside from selectivity over other DUB enzymes, it is important for a drug to
have low affinity for other
targets, and pharmacological profiling may be performed against panels of
targets to assess the potential
for, and to minimise, potential off-target effects. Examples of targets for
which the compounds of the
present invention may be screened against are those of the industry standard
Eurofins-Cerep
SafetyScreen44 panel, which includes 44 targets as a representative selection
of GPCR receptors,
transporters, ion channels, nuclear receptors, and kinase and non-kinase
enzymes. Preferably,
compounds of the invention have insignificant affinity against targets of this
screening panel. Further
examples of targets for which the compounds of the present invention may be
screened against are
kinases of the Thermo Fisher SelectScreen kinase profiling panel, which
includes 39 targets as a
representative selection of kinase enzymes. Preferably, compounds of the
invention have insignificant
affinity against targets of this screening panel. Additionally, examples of a
particular enzyme class for
which the compounds of the present invention may be screened against are the
cathepsins (e.g. cathepsin
A, B, C, H, K, L, L2, S, V and Z). Preferably, compounds of the invention have
good selectivity for
USP30 over one or more of these enzymes.
There is also a need for compounds that have favourable pharmacokinetic
properties such that they are
suitable for oral administration. An orally administered drug should have good
bioavailability; that is
an ability to readily cross the gastrointestinal (GI) tract and not be subject
to extensive metabolism as it
passes from the GI tract into the systemic circulation. Once a drug is in the
systemic circulation the
rate of metabolism is also important in determining the time of residence of
the drug in the body.
Thus, it is clearly favourable for drug molecules to have the properties of
being readily able to cross the
GI tract and being only slowly metabolised in the body. The Caco-2 assay is a
widely accepted model
8
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
for predicting the ability of a given molecule to cross the GI tract. The
majority of metabolism of drug
molecules generally occurs in the liver, and in vitro assays using whole cell
hepatocytes (animal or
human) are widely accepted methods for measuring the susceptibility of a given
molecule towards
metabolism in the liver. Such assays aim to predict in vivo clearance from the
hepatocyte calculated
clearance value.
Compounds which have good Caco-2 flux and are stable towards hepatocytes are
predicted to have
good oral bioavailability (good absorption across the GI tract and minimal
extraction of compound as
it passes through the liver) and a long residence time in the body that is
sufficient for the drug to be
efficacious.
The solubility of a compound is an important factor in achieving a desired
concentration of drug in
systemic circulation for the anticipated pharmacological response. Low aqueous
solubility is a problem
encountered with formulation development of new chemical entities and to be
absorbed a drug must be
present in the form of solution at the site of absorption. The kinetic
solubility of a compound may be
measured using a turbidimetric solubility assay, the data from which may also
be used in conjunction
with Caco-2 permeability data to predict dose dependent human intestinal
absorption.
Other parameters that may be measured using standard assays that are
indicative of a compound's
exposure profile include, for example plasma stability (half-life
measurement), blood AUC, Cmax, Cram
and Tmax values.
The treatment of CNS disorders, including Alzheimer's disease, Parkinson's
disease, and other
disorders described herein, requires drug molecules to target the brain, which
requires adequate
penetration of the blood brain barrier. There is, therefore, a need for USP30
inhibitors that possess
effective blood brain penetration properties and provide suitable residence
time in the brain to be
efficacious. The probability that a compound can cross the blood brain barrier
may be measured by an
in vitro flux assay utilizing a MDR1-MDCK cell monolayer (Madin-Darby Canine
Kidney cells
transfected with MDR-1 resulting in overexpression of the human efflux
transporter P-glycoprotein).
Additionally, exposure may also be measured directly in brain and plasma using
in vivo animal models.
There is also a need for compounds that have a favourable safety profile,
which may be measured by a
variety of standard in vitro and in vivo methods. A cell toxicity counter-
screen may be used to assay
the anti-proliferative/cytotoxic effect in a particular cell line (e.g.
HCT116) by fluorometric detection
of rezasurin (alamarBlueTM) to resofurin in response to mitochondrial
activity.
Toxicology and safety studies may also be conducted to identify potential
target organs for adverse
effects and define the Therapeutic Index to set the initial starting doses in
clinical trials. Regulatory
requirements generally require studies to be conducted in at least two
laboratory animal species, one
rodent (rat or mouse) and one nonrodent (rabbit, dog, non-human primate, or
other suitable species).
9
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
The bacterial reverse mutation assay (Ames Test) may be used to evaluate the
mutagenic properties of
compounds of the invention, commonly by using the bacterial strain Salmonella
typhimurium, which
is mutant for the biosynthesis of the amino acid histidine.
The micronucleus assay may be used to determine if a compound is genotoxic by
evaluating the
presence of micronuclei. Micronuclei may contain chromosome fragments produced
from DNA
breakage (clastogens) or whole chromosomes produced by disruption of the
mitotic apparatus
(aneugens).
The hERG predictor assay provides valuable information about the possible
binding of test compounds
to the potassium channel and potential QT prolongation on echocardiogram.
Inhibition of the hERG
current causes QT interval prolongation resulting in potentially fatal
ventricular tachyarrhythmia
(Torsades de Pointes). Typically, assay data may be generated from an
automated patch-clamp assay
platform.
The present invention is therefore directed to USP30 inhibitors that have
suitable and/or improved
properties in order to maximise efficacy against the target disease. Such
properties include, for
example, potency, selectivity, physicochemical properties, ADME (absorption,
distribution,
metabolism and excretion) properties, including PK (pharmacokinetic) profile,
and safety profile.
The most preferred compound of the present invention is highly potent for
USP30 as measured in the
biochemical assay described herein and is significantly more selective for
USP30 over other DUBs and
cathepsins. The significant and unexpected properties of the compounds of the
present invention make
them particularly suitable for use in the treatment and/or prevention of
diseases linked to USP30
activity.
According to a first aspect, the present invention provides a compound of
formula (I):
N ____________________________________________________ =N
N
CN CH3
or a pharmaceutically acceptable salt thereof
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
In a first preferred aspect, the present invention provides a compound of
formula (IA):
N 22,--\
N ___________________________________________________ =N
N
(R)
CN
CH3
or a pharmaceutically acceptable salt thereof.
In a second preferred aspect, the present invention provides a compound of
formula (TB):
N'r)
N ___________________________________________________ =N
(R)
CN
tH3
or a pharmaceutically acceptable salt thereof
In a third preferred aspect, the present invention provides a compound of
formula (IC):
r")-(< õõ,.
N ___________________________________________________ =N
CN CH3
or a pharmaceutically acceptable salt thereof
In a fourth preferred aspect, the present invention provides a compound of
formula (ID):
cz
N ___________________________________________________ =N
(s)
CN CH3
or a pharmaceutically acceptable salt thereof
11
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
Preferred compounds of formula (I) are selected from:
(3 aR,4R,6aR)-1 -(5 -(2-cyanopyridin-4-yl)oxazole -2-carbony1)-4-
methylhexahydropyrrolo [3 ,4 -
blpyrrole-5(1H)-carbonitrile;
(3 aS,4S,6aS)-1 -(5 -(2-cyanopyridin -4-yl)oxazole -2-carbony1)-4-
methylhexahydropyrrolo 113,4-
blpyrrole-5(1H)-carbonitrile;
(3 aR,4S,6aR)-1 -(5 -(2-cyanopyridin -4-yl)oxazole -2-carbony1)-4-
methylhexahydropyrrolo [3,4-
blpyrrole-5(1H)-carbonitrile;
(3 aS,4R,6aS)-1 -(5 -(2-cyanopyridin -4-yl)oxazole -2-carbony1)-4-
methylhexahydropyrrolo [3,4-
blpyrrole-5(1H)-carbonitrile;
(3 aR,4R,6aS)-1 -(5 -(2-cyanopyridin-4-yl)oxazole -2-carbony1)-4-
methylhexahydropyrrolo [3,4-
blpyrrole-5(1H)-carbonitrile;
(3 aS,4S,6aR)-1 -(5 -(2-cyanopyridin -4-yl)oxazole -2-carbony1)-4-
methylhexahydropyrrolo [3,4-
blpyrrole-5(1H)-carbonitrile;
(3 aR,4S,6aS)-1 -(5 -(2-cyanopyridin -4-yl)oxazole -2-carbony1)-4-
methylhexahydropyrrolo 113,4-
blpyrrole-5(1H)-carbonitrile; and
(3 aS,4R,6aR)-1 -(5 -(2-cyanopyridin -4-yl)oxazole -2-carbony1)-4-
methylhexahydropyrrolo [3,4-
blpyrrole-5(1H)-carbonitrile;
or a pharmaceutically acceptable salt thereof.
More preferred compounds of formula (I) are selected from:
(3 aR,4R,6aR)-1 -(5 -(2-cyanopyridin-4-yl)oxazole -2-carbony1)-4-
methylhexahydropyrrolo [3 ,4 -
blpyrrole-5(1H)-carbonitrile;
(3 aS,4S,6aS)-1 -(5 -(2-cyanopyridin -4-yl)oxazole -2-carbony1)-4-
methylhexahydropyrrolo [3,4-
blpyrrole-5(1H)-carbonitrile;
(3 aR,4S,6aR)-1 -(5 -(2-cyanopyridin-4-yl)oxazole -2-carbony1)-4-
methylhexahydropyrrolo 113,4-
blpyrrole-5(1H)-carbonitrile; and
(3 aS,4R,6aS)-1 -(5 -(2-cyanopyridin -4-yl)oxazole -2-carbony1)-4-
methylhexahydropyrrolo [3,4-
blpyrrole-5(1H)-carbonitrile;
or a pharmaceutically acceptable salt thereof.
The most preferred compound of formula (I) is:
(3 aR,4R,6aR)-1 -(5 -(2-cyanopyridin-4-yl)oxazole -2-carbony1)-4-
methylhexahydropyrrolo 113 ,4 -b] pyrrole -5 (1H)-carbonitrile ;
or a pharmaceutically acceptable salt thereof.
Example 1 is the most preferred compound of the invention.
12
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
This most preferred compound of formula (I) exists as a single, dextrorotatory
stereoisomer, which has
been identified as having the following structure with the absolute
configuration shown:
=N
N 3a
CN
tH3
(3aR,4R,6aR)-1-(5 -(2-cyanopyridin-4-yl)oxazole -2-carbony1)-4-
methylhexahydropyrrolo [3 ,4 -b] pyrrole -5 (1H)-carbonitrile .
The compound of formula (I) possesses three chiral centres and may therefore
exist in eight
stereochemical configurations. The synthesis of the bicyclic ring, according
to the experimental below,
is believed to produce the cis-fused ring system, giving rise to four possible
stereoisomers. The
stereochemical configuration of the most preferred compound of formula (I) is
that of Example 1, which
is the compound that is the most active against USP30 in the biochemical
assay.
Four stereoisomers have been prepared by the experiments described below;
Examples 1 to 4.
Examples 1 and 3 are dextrorotatory, and Examples 2 and 4 are levororotatory,
when measured under
the experimental conditions; (c = 0.05 g/100 cm', Me0H). Example 1, when
prepared by two different
methods, produced optical rotation measurements of N1D25 = +208 and +204 .
The small variation
may be due to experimental differences or differences in optical purity.
Example 3 produced an optical
rotation measurement of [a1D25 = +166 .
The present invention is directed, additionally, to the cis-fused stereoisomer
that is dextrorotatory when
measured as described and has an approximate optical rotation in the region of
+204 to +208 .
Depending on the optical purity, this stereoisomer, when substantially pure,
may produce an optical
rotation in the region of +190 to +220 . Such a figure clearly distinguishes
this compound of the
invention from the other cis-fused stereoisomer that is also dextrorotatory.
The present invention is directed, additionally, to:
(+)-(3aR*,4R*,6aR*)-1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbony1)-4-
methylhexahydropyrrolo [3 ,4-
pyrrole-5(1H)-carbonitrile (I);
or a pharmaceutically acceptable salt thereof
The present invention is directed, additionally, to the major stereoisomer
produced by the experimental
procedure of Example 1.
Pharmaceutical acceptable salts of the compounds of formula (I) include the
acid addition and base salts
(including di-salts) thereof
13
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
Suitable acid addition salts are formed from acids which form non-toxic salts.
Examples include the
acetate, aspartate, benzoate, besylate, bicarbonate/carbonate, bisulfate,
camsylate, citrate, edisylate,
esylate, fumarate, gluceptate, gluconate, glucuronate, hibenzate,
hydrochloride/chloride,
hydrobromide/bromide, hydroiodide/iodide, hydrogen phosphate, isethionate, D-
and L-lactate, malate,
maleate, malonate, mesylate, methylsulfate, 2-napsylate, nicotinate, nitrate,
orotate, palmate,
phosphate, saccharate, stearate, succinate sulfate, D-and L-tartrate, and
tosylate salts.
Suitable base salts are formed from bases which form non-toxic salts. Examples
include the aluminium,
ammonium, arginine, benzathine, calcium, choline, diethylamine, diolamine,
glycine, lysine,
magnesium, meglumine, olamine, potassium, sodium, tromethamine and zinc salts.
For a review on suitable salts, see Stahl and Wermuth, Handbook of
Pharmaceutical Salts: Properties,
Selection, and Use, Wiley-VCH, Weinheim, Germany (2002).
A pharmaceutical acceptable salt of a compound of formula (I) may be readily
prepared by mixing
together solutions of the compound of formula (I) and the desired acid or
base, as appropriate. The salt
may precipitate from solution and be collected by filtration or may be
recovered by evaporation of the
solvent.
Pharmaceutical acceptable solvates in accordance with the invention include
hydrates and solvates
wherein the solvent of crystallization may be isotopically substituted, e.g.
D20, acetone-d6, DMSO-d6.
Also, within the scope of the invention are clathrates, drug-host inclusion
complexes wherein, in
contrast to the aforementioned solvates, the drug and host are present in non-
stoichiometric amounts.
For a review of such complexes, see J. Pharm Sci, 64 (8), 1269-1288 by
Haleblian (August 1975).
Hereinafter all references to compounds of formula (I) include references to
salts thereof and to solvates
and clathrates of compounds of formula (I) and salts thereof.
The invention includes all polymorphs of the compounds of formula (I) as
hereinbefore defined.
Also, within the scope of the invention are so-called "prodrugs" of the
compounds of formula (I). Thus,
certain derivatives of compounds of formula (I) which have little or no
pharmacological activity
themselves can, when metabolised upon administration into or onto the body,
give rise to compounds
of formula (I) having the desired activity. Such derivatives are referred to
as "prodrugs".
Prodrugs in accordance with the invention can, for example, be produced by
replacing appropriate
functionalities present in the compounds of formula (I) with certain moieties
known to those skilled in
the art as "pro-moieties" as described, for example, in "Design of Prodrugs"
by H Bundgaard (Elsevier,
1985).
Finally, certain compounds of formula (I) may themselves act as prodrugs of
other compounds of
formula (I).
14
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
Certain derivatives of compounds of formula (I) which contain a nitrogen atom
may also form the
corresponding N-oxide, and such compounds are also within the scope of the
present invention.
Included within the scope of the present invention are all tautomeric forms of
the compounds of
formula (I).
Conventional techniques for the preparation/isolation of individual
enantiomers include chiral synthesis
from a suitable optically pure precursor or resolution of the racemate (or the
racemate of a salt or
derivative) using, for example, chiral high performance liquid chromatography
(HPLC). Alternatively,
the racemate (or a racemic precursor) may be reacted with a suitable optically
active compound, for
example, an alcohol, or, in the case where the compound of formula (I)
contains an acidic or basic
moiety, a base or acid such as 1-phenylethylamine or tartaric acid. The
resulting diastereomeric mixture
may be separated by chromatography and/or fractional crystallization and one
or both of the
diastereoisomers converted to the corresponding pure enantiomer(s) by means
well known to a skilled
person. Chiral compounds of the invention (and chiral precursors thereof) may
be obtained in
enantiomerically-enriched form using chromatography, typically HPLC, on an
asymmetric resin with a
mobile phase consisting of a hydrocarbon, typically heptane or hexane,
containing from 0 to 50% by
volume of propan-2-ol, typically from 2% to 20%, and from 0 to 5% by volume of
an alkylamine,
typically 0.1% diethylamine. Concentration of the eluate affords the enriched
mixture. The present
invention includes all crystal forms of the compounds of formula (I) including
racemates and racemic
mixtures (conglomerates) thereof Stereoisomeric conglomerates may be separated
by conventional
techniques known to those skilled in the art - see, for example,
"Stereochemistry of Organic
Compounds" by E. L. Eliel and S. H. Wilen (Wiley, New York, 1994).
The most preferred compound of formula (I) of the present invention may exist
in combination with
one or more other stereoisomers of the preferred compounds of formula (I). For
example, the compound
may exist with its enantiomer, i.e. as a racemate, or it may exist with a
diastereomer.
The preferred compounds of formula (I) of the present invention preferably
exist as a single
stereoisomer. The preferred compounds of formula (I) are isolated as single
stereoisomers and may
exist with a stereoisomeric excess of at least 60%, preferably at least 80%,
more preferably at least 90%,
more preferably at least 95%, for example 96%, 97%, 98%, 99%, or 100%. The
stereoisomeric excess
may be a measure of an enantiomeric excess or may be a measure of a
diasteromeric ratio.
The present invention also includes all pharmaceutically acceptable isotopic
variations of a compound
of formula (I). An isotopic variation is defined as one in which at least one
atom is replaced by an atom
having the same atomic number, but an atomic mass different from the atomic
mass usually found in
nature.
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
Examples of isotopes suitable for inclusion in the compounds of the invention
include isotopes of
hydrogen, such as 2H and 3H, carbon, such as "C and "C, nitrogen, such as "N,
oxygen, such as 170
and 180, phosphorus, such as 32P, sulfur, such as "S, fluorine, such as "F,
and chlorine, such as 36C1.
Substitution of the compounds of the invention with isotopes such as deuterium
may afford certain
therapeutic advantages resulting from greater metabolic stability, for
example, increased in vivo half-
life or reduced dosage requirements, and hence may be preferred in some
circumstances.
Certain isotopic variations of the compounds of formula (I), for example,
those incorporating a
radioactive isotope, are useful in drug and/or substrate tissue distribution
studies. The radioactive
isotopes tritium, and "C, are particularly useful for this purpose in view of
their ease of incorporation
and ready means of detection.
Isotopic variations of the compounds of formula (I) can generally be prepared
by conventional
techniques known to those skilled in the art or by processes analogous to
those described in the
accompanying Examples and Preparations using appropriate isotopic variations
of suitable reagents.
The compounds of formula (I) are inhibitors of the deubiquitylating enzyme
USP30.
According to a further aspect, the present invention provides a compound of
formula (I) as defined
herein, a tautomer thereof, or a pharmaceutically acceptable salt of said
compound or tautomer for use
as a medicament.
According to a further aspect, the present invention provides a method of
treatment or prevention of a
disorder or condition where inhibition of USP30 is known, or can be shown, to
produce a beneficial
effect, in a mammal, comprising administering to said mammal a therapeutically
effective amount of a
compound of formula (I) as defined herein, a tautomer thereof, or a
pharmaceutically acceptable salt of
said compound or tautomer.
According to a further aspect, the present invention provides the use of a
compound of formula (I) as
defined herein, a tautomer thereof, or a pharmaceutically acceptable salt of
said compound or tautomer,
in the manufacture of a medicament for the treatment or prevention of a
disorder or condition where
inhibition of USP30 is known, or can be shown, to produce a beneficial effect.
The manufacture of a
medicament may include, inter alia, the chemical synthesis of the compound of
formula (I) or a salt
thereof, or the preparation of a composition or formulation comprising the
compound or salt, or the
packaging of any medicament comprising the compound.
According to a further aspect, the present invention provides a method of
inhibition of USP30 in a
patient comprising administering to the patient a therapeutically effective
amount of a compound of
formula (I) as defined herein, a tautomer thereof, or a pharmaceutically
acceptable salt of said
compound or tautomer.
16
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
The disorder or condition benefiting from USP30 activity is selected from a
condition involving
mitochondrial dysfunction, cancer and fibrosis.
In one preferred embodiment of all aspects of the invention, the disorder or
condition benefiting from
USP30 activity is a condition involving mitochondrial dysfunction.
Mitochondrial dysfunctions result from defects of the mitochondria, which are
specialized
compartments present in every cell of the body except red blood cells. When
mitochondria fail, less
and less energy is generated within the cell and cell injury or even cell
death will follow. If this process
is repeated throughout the body the life of the subject in whom this is
happening is severely
compromised. Diseases of the mitochondria appear most often in organs that are
very energy
demanding such as the brain, heart, liver, skeletal muscles, kidney and the
endocrine and respiratory
system.
The condition involving mitochondrial dysfunction may be selected from a
condition involving a
mitophagy defect, a condition involving a mutation in mitochondrial DNA, a
condition involving
mitochondrial oxidative stress, a condition involving a defect in
mitochondrial membrane potential,
mitochondrial biogenesis, a condition involving a defect in mitochondrial
shape or morphology, and a
condition involving a lysosomal storage defect.
In particular, the condition involving mitochondrial dysfunction may be
selected from a
neurodegenerative disease; multiple sclerosis (MS); mitochondrial
encephalopathy, lactic acidosis and
stroke-like episodes (MELAS) syndrome; materially-inherited diabetes and
deafness (MIDD); Leber's
hereditary optic neuropathy (LHON); cancer (including, for example, breast,
ovarian, prostate, lung,
kidney, gastric, colon, testicular, head and neck, pancreas, brain, melanoma,
bone or other cancers of
tissue organs and cancers of the blood cells, such as lymphoma and leukaemia,
multiple myeloma,
metastatic carcinoma, osteosarcoma, chondosarcoma, Ewing's sarcoma,
nasopharyngeal carcinoma,
colorectal cancer, and non-small cell lung carcinoma); neuropathy, ataxia,
retinitis pigmentosa,
maternally inherited Leigh syndrome (NARP-MILS); Danon disease; diabetes;
diabetic nephropathy;
metabolic disorders; heart failure; ischemic heart disease leading to
myocardial infarction; psychiatric
diseases, for example schizophrenia; multiple sulfatase deficiency (MSD);
mucolipidosis II (ML II);
mucolipidosis III (ML III); mucolipidosis IV (ML IV); GM1-gangliosidosis
(GM1); neuronal ceroid-
lipofuscinoses (NCL1); Alpers disease; Barth syndrome; beta-oxidation defects;
carnitine-acyl-
carnitine deficiency; carnitine deficiency; creatine deficiency syndromes; co-
enzyme Q10 deficiency;
complex I deficiency; complex II deficiency; complex III deficiency; complex
IV deficiency; complex
V deficiency; COX deficiency; chronic progressive external ophthalmoplegia
syndrome (CPEO); CPT I
deficiency; CPT II deficiency; glutaric aciduria type II; Kearns-Sayre
syndrome; lactic acidosis; long-
chain acyl-CoA dehydrogenase deficiency (LCHAD); Leigh disease or syndrome;
Leigh syndrome
French Canadian (LSFC) variant; lethal infantile cardiomyopathy (LIC); Luft
disease; medium-chain
17
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
acyl-CoA dehydrogenase deficiency (MCAD); myoclonic epilepsy and ragged-red
fiber (MERRF)
syndrome; mitochondrial cytopathy; mitochondrial recessive ataxia syndrome;
mitochondrial DNA
depletion syndrome; myoneurogastointestinal disorder and encephalopathy;
Pearson syndrome;
pyruvate dehydrogenase deficiency; pyruvate carboxylase deficiency; POLG
mutations; medium/short-
chain 3-hydroxyacyl-CoA dehydrogenase (M/SCHAD) deficiency; very long-chain
acyl-CoA
dehydrogenase (VLCAD) deficiency; peroxisomal disorders; methylmalonic
acidemia; mevalonate
kinase deficiency; age-dependent decline in cognitive function and muscle
strength; and cognitive
impairment associated with neurodegenerative and neuropsychiatric disorders.
The condition involving mitochondrial dysfunction may be a CNS disorder, for
example a
neurodegenerative disease.
Neurodegenerative diseases include, but are not limited to, Parkinson's
disease, Alzheimer's disease,
amyotrophic lateral sclerosis (ALS), Huntington's disease, ischemia, stroke,
dementia with Lewy
bodies, multiple system atrophy (MSA), progressive supranuclear palsy (PSP),
corticobasal
degeneration (CBD), and frontotemporal dementia.
In particular, the compounds of the invention may be useful in the treatment
or prevention of
Parkinson's disease, including, but not limited to, PD related to mutations in
a-synuclein, parkin,
PINK', GBA, and LRRK2, and autosomal recessive juvenile Parkinson's disease
(AR-JP) or early
onset Parkinson's disease (EOPD), where parkin or PINK1 is mutated, truncated,
or deleted.
In particular, the compounds of the invention may be useful in treatment of
cognitive impairment
associated with neurodegenerative and neuropsychiatric disorders, including,
for example, cognitive
impairment associated with Alzheimer's disease and Parkinson's disease,
preclinical or prodromal
forms of AD and PD, Huntington's disease, dementia with lewy body disease,
cognitive impairment
associated with schizophrenia, mood disorders, bipolar and major depressive
disorders.
The compounds of the invention or pharmaceutical compositions thereof as
described herein may be
combined with one or more additional agents when used for the treatment or
prevention of conditions
involving mitochondrial dysfunction. The compounds may be combined with one or
more additional
agents selected from levodopa, a dopamine agonist, a monoamino oxygenase (MAO)
B inhibitor, a
catechol 0-methyltransferase (COMT) inhibitor, an anticholinergic, riluzole,
amantadine, a
cholinesterase inhibitor, memantine, tetrabenazine, an antipsychotic,
diazepam, clonazepam, an
antidepressant, and an anti-convulsant. The compounds may be combined with
agents which
reduce/remove pathogenic protein aggregates in neurodegenerative diseases,
such as agents which
reduce/remove alpha-synuclein in Parkinson's disease, multiple system atrophy
or dementia with Lewy
bodies; agents which reduce/remove Tau in Alzheimer's disease or progressive
supranuclear palsy;
agents which reduce/remove TDP-43 in ALS or frontotemporal dementia.
18
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
In another preferred embodiment of all aspects of the invention, the disorder
or condition benefiting
from USP30 activity is cancer. The cancer may be linked to mitochondrial
dysfunction. Preferred
cancers include, for example, breast, ovarian, prostate, lung, kidney,
gastric, colon, testicular, head and
neck, pancreas, brain, melanoma, bone or other cancers of tissue organs and
cancers of the blood cells,
such as lymphoma and leukaemia, multiple myeloma, metastatic carcinoma,
osteosarcoma,
chondo sarcoma, Ewing's sarcoma, nasopharyngeal carcinoma, colorectal cancer,
colorectal cancer, and
non-small cell lung carcinoma.
In particular, the compounds of the invention may be useful in the treatment
or prevention of cancer
where apoptotic pathways are dysregulated and more particularly where proteins
of the BCL-2 family
are mutated, or over or under expressed.
Fibrosis refers to the accumulation of extracellular matrix constituents that
occurs following trauma,
inflammation, tissue repair, immunological reactions, cellular hyperplasia,
and neoplasia. Fibrotic
disorders that may be treated by the compounds and compositions of the present
invention include, inter
alia, fibrosis/fibrotic disorders associated with major organ diseases, for
example, interstitial lung
disease (ILD), liver cirrhosis, non-alcoholic fatty liver disease (NAFLD) and
non-alcoholic
steatohepatitis (NASH) (hepatic fibrosis), kidney disease (renal fibrosis),
acute kidney injury (AKI),
acute kidney disease (AKD), chronic kidney disease (CKD), delayed kidney graft
function, heart or
vascular disease (cardiac fibrosis) and diseases of the eye;
fibroproliferative disorders, for example,
systemic and local scleroderma, keloids and hypertrophic scars,
atherosclerosis, restenosis, and
Dupuytren's contracture; scarring associated with trauma, for example,
surgical complications,
chemotherapeutics drug-induced fibrosis (e.g. bleomycin-induced fibrosis),
radiation-induced fibrosis,
accidental injury and burns); retroperitoneal fibrosis (Ormond's disease); and
peritoneal
fibrosis/peritoneal scarring in patients receiving peritoneal dialysis,
usually following renal
transplantation. See, for example, Wynn et al, 2004, Nat Rev Immunol. August;
4(8): 583-594. The
present invention therefore relates to methods of treatment or prevention, and
compounds and
compositions used in said methods, of fibrosis/fibrotic disorders of and/or
associated with the major
organs, including for example, the lung, liver, kidney, heart, skin, eye,
gastrointestinal tract, peritoneum
and bone marrow, and other diseases/disorders herein described.
The compounds may be combined with agents which are used as treatments for
kidney disease,
including anti-diabetic agents, cardiovascular disease agents, and novel
agents targeting disease
relevant pathways such as oxidative stress (including, but not limited to, the
nrf2/keap-1 pathway) and
anti-apoptotic pathways (including, but not limited to, anti p53 agents).
Interstitial lung disease (ILD) includes disorders in which pulmonary
inflammation and fibrosis are the
final common pathways of pathology, for example, sarcoidosis, silicosis, drug
reactions, infections and
collagen vascular diseases, such as rheumatoid arthritis and systemic
sclerosis (scleroderma). The
19
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
fibrotic disorder of the lung includes, for example, pulmonary fibrosis,
idiopathic pulmonary fibrosis
(IPF), usual interstitial pneumonitis (UIP), interstitial lung disease,
cryptogenic fibrosing alveolitis
(CFA), bronchiolitis obliterans, and bronchiectasis.
Idiopathic pulmonary fibrosis (IPF) is the most common type of ILD and has no
known cause.
The compounds may be combined with agents which are treatments for IPF and
potentially for ILD,
including nintedanib and pirfenidone.
Liver cirrhosis has similar causes to ILD and includes, for example, cirrhosis
associated with viral
hepatitis, schistosomiasis and chronic alcoholism.
Kidney disease may be associated with diabetes, which can damage and scar the
kidneys leading to a
progressive loss of function, and also hypertensive diseases. Kidney fibrosis
may occur at any stage of
kidney disease, from acute kidney disease (AKD) post injury and chronic kidney
disease (CKD), such
as incident CKD and progressive CKD, through to end-stage renal disease
(ESRD). Kidney fibrosis
can develop as a result of cardiovascular disease such as hypertension or
diabetes, both of which place
immense strain on kidney function which promotes a fibrotic response. However,
kidney fibrosis can
also be idiopathic (without a known cause), and certain genetic mitochondrial
diseases also present
kidney fibrosis manifestations and associated symptoms.
Heart disease may result in scar tissue that can impair the ability of the
heart to pump.
Diseases of the eye include, for example, macular degeneration and retinal and
vitreal retinopathy,
which can impair vision.
In a preferred embodiment, the present invention is directed to the treatment
or prevention of idiopathic
pulmonary fibrosis (IPF).
In another preferred embodiment, the present invention is directed to the
treatment or prevention of
kidney fibrosis.
In another preferred embodiment, the present invention is directed to the
treatment or prevention of
acute kidney injury (AKI), especially in high risk patients. Examples include
post-surgical AKI, for
example organ transplantation, such as due to ischemia reperfusion injury,
delayed graft function;
oncology, such as AKI due to chemotherapy; contrast medium-induced
nephropathy, such as direct-
tubular cytotoxicity, hemodynamic ischemia and osmotic effects; acute
interstitial nephritis, such as
due to drugs or infection; AKI due to obstruction such as kidney stones; and
COVID-19-induced AKI.
A particular high risk patient sub-group are those undergoing cardiac surgery,
for example, coronary
artery bypass graft and/or valve surgery. There are established static risk
factors for AKI such as age
65 years or over, insulin dependent diabetes, CKD (adults with an estimated
glomerular filtration rate
[eGFR] less than 60 ml/min/1.73 m2 are at particular risk), heart failure,
liver disease, history of AKI.
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
In another preferred embodiment, the present invention is directed to the
treatment or prevention of
acute kidney disease (AKD) or chronic kidney disease (CKD) stemming from such
AKI, including for
example, tubulointerstitial fibrosis and diabetic nephropathy.
In another preferred embodiment, the present invention is directed to the
treatment or prevention of
liver diseases, including but not limited to NAFLD, NASH, liver cirrhosis,
portal hypertension, acute
liver failure, and hepatocellular carcinoma. Liver disease such as NAFLD and
NASH may be associated
with various metabolic conditions such as metabolic syndrome and Type II
diabetes, which also would
increase risk for various diabetes associated pathologies, including diabetic
retinopathy and peripiheral
neuropathies.
The compounds of the invention or pharmaceutical compositions thereof as
described herein may be
combined with one or more additional agents when used for the treatment or
prevention of conditions
involving liver disease and metabolic dysfunction, including metformin,
sulfonylureas, DPP-4
inhibitors, GLP-1 agonists, PPAR agonists, SGLT2 inhibitors, angiotensin-
converting enzyme (ACE)
inhibitors and angiotensin II receptor blockers (ARBs).
Leigh syndrome is a rare inherited neurometabolic disorder that affects the
central nervous system. This
progressive disorder begins in infants between the ages of three months and
two years. Rarely, it occurs
in teenagers and adults. Leigh syndrome can be caused by mutations in nuclear
DNA encoding for
mitochondrial proteins, mutations in mitochondrial DNA (maternally inherited
Leigh syndrome ¨
MILS), or by deficiencies of an enzyme called pyruvate dehydrogenase located
on the short arm of the
X Chromosome (X-linked Leigh syndrome). Symptoms of Leigh syndrome usually
progress rapidly.
The earliest signs may be poor sucking ability, and the loss of head control
and motor skills. These
symptoms may be accompanied by loss of appetite, vomiting, irritability,
continuous crying, and
seizures. As the disorder progresses, symptoms may also include generalized
weakness, lack of muscle
tone, and episodes of lactic acidosis, which can lead to impairment of
respiratory and kidney function.
In maternally inherited Leigh syndrome (MILS), genetic mutations in
mitochondrial DNA (at a high
proportion of >90%) interfere with the energy sources that run cells in an
area of the brain that plays a
role in motor movements. Genetic mutations in mitochondrial DNA result in a
chronic lack of energy
in these cells, which in turn affects the central nervous system and causes
progressive degeneration of
motor functions. When the genetic mutations in mitochondrial DNA that causes
MILS are less abundant
(less than 90%), the condition is known as neuropathy ataxia and retinitis
pigmentosa (NARP). There
is also a form of Leigh's disease (called X-linked Leigh's disease) which is
the result of mutations in a
gene that produces another group of substances that are important for cell
metabolism. A further variant
of Leigh syndrome exists which is called French Canadian variant,
characterized by mutations in a gene
called LRPPRC. Similar neurological symptoms are expressed as those for Leigh
syndrome, although
Liver Steatosis is commonly also observed in the French Canadian variant.
21
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
In a preferred embodiment, the present invention is directed to the treatment
or prevention of Leigh
syndrome or disease, including for example, X-linked Leigh's disease, Leigh
syndrome French
Canadian variant, and/or the symptoms associated with Leigh's disease.
The compounds may be combined with novel agents which may be used as
treatments for mitochondrial
disease, including, but not limited to, nicotinamide riboside.
References to 'treatment' includes means to ameliorate, alleviate symptoms,
eliminate the causation of
the symptoms either on a temporary or permanent basis. The compounds of the
invention are useful in
the treatment of the diseases disclosed herein in humans and other mammals.
In another embodiment, the invention encompasses prophylactic therapy of the
diseases disclosed
herein and includes means to prevent or slow the appearance of symptoms of the
named disorder or
condition. The compounds of the invention are useful in the prevention of the
diseases disclosed herein
in humans and other mammals.
A patient in need of treatment or prevention may, for example, be a human or
other mammal suffering
from the condition or at risk of suffering from the condition.
According to a further aspect, the present invention provides a pharmaceutical
composition comprising
a compound of formula (I) as defined herein, or a pharmaceutically acceptable
salt of said compound
or tautomer, together with a pharmaceutically acceptable diluent or carrier.
Pharmaceutical compositions of the invention comprise any of the compounds of
the invention
combined with any pharmaceutically acceptable carrier, adjuvant or vehicle.
Examples of
pharmaceutically acceptable carriers are known to those skilled in the art and
include, but are not limited
to, preserving agents, fillers, disintegrating agents, wetting agents,
emulsifying agents, suspending
agents, sweetening agents, flavouring agents, perfuming agents, antibacterial
agents, antifungal agents,
lubricating agents and dispersing agents, depending on the nature of the mode
of administration and
dosage forms. The compositions may be in the form of, for example, tablets,
capsules, powders,
granules, elixirs, lozenges, suppositories, syrups and liquid preparations
including suspensions and
solutions. The term "pharmaceutical composition" in the context of this
invention means a composition
comprising an active agent and comprising additionally one or more
pharmaceutically acceptable
carriers. The composition may further contain ingredients selected from, for
example, diluents,
adjuvants, excipients, vehicles, preserving agents, fillers, disintegrating
agents, wetting agents,
emulsifying agents, suspending agents, sweetening agents, flavouring agents,
perfuming agents,
antibacterial agents, antifungal agents, lubricating agents and dispersing
agents, depending on the nature
of the mode of administration and dosage forms.
The compounds of the invention or pharmaceutical compositions thereof, as
described herein, may be
used alone or combined with one or more additional pharmaceutical agents. The
compounds may be
22
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
combined with an additional anti-tumour therapeutic agent, for example,
chemotherapeutic drugs or
inhibitors of other regulatory proteins. In one embodiment, the additional
anti-tumour therapeutic agent
is a BH-3 mimetic. In a further embodiment, BH-3 mimetics may be selected from
but not limited to
one or more of ABT-737, ABT-199, ABT-263, and Obatoclax. In a further
embodiment, the additional
anti-tumour agent is a chemotherapeutic agent. Chemotherapeutic agents may be
selected from but not
limited to, olaparib, mitomycin C, cisplatin, carboplatin, oxaliplatin,
ionizing radiation (IR),
camptothecin, irinotecan, topotecan, temozolomide, taxanes, 5-
fluoropyrimidines, gemcitabine, and
doxorubicin.
For the treatment or prevention of fibrotic disorders, for example, the
compounds of the invention or
pharmaceutical compositions thereof, as described herein, may be used alone or
combined with one or
more additional pharmaceutical agents selected from the group consisting of
anticholinergic agents,
beta-2 mimetics, steroids, PDE-IV inhibitors, p38 MAP kinase inhibitors, NK1
antagonists, LTD4
antagonists, EGFR inhibitors and endothelin antagonists.
In particular, the compounds of the invention or pharmaceutical compositions
thereof, as described
herein, may be used alone or combined with one or more additional
pharmaceutical agents selected
from the group consisting of general immunosuppressive drugs, such as a
corticosteroid,
immunosuppressive or cytotoxic agents, or antifibrotics, such as pirfenidone
or a non-specific kinase
inhibitor (e.g. nintedanib).
The pharmaceutical compositions of the invention may be administered in any
suitably effective
manner, such as oral, parenteral, topical, inhaled, intranasal, rectal,
intravaginal, ocular and aural.
Pharmaceutical compositions suitable for the delivery of compounds of the
present invention and
methods for their preparation will be readily apparent to those skilled in the
art. Such compositions and
methods for their preparation may be found, for example, in "Remington's
Pharmaceutical Sciences",
19th Edition (Mack Publishing Company, 1995).
Oral Administration
The compounds of the invention may be administered orally. Oral administration
may involve
swallowing, so that the compound enters the gastrointestinal tract, or buccal
or sublingual
administration may be employed by which the compound enters the blood stream
directly from the
mouth.
Formulations suitable for oral administration include solid formulations such
as tablets, capsules
containing particulates, liquids, or powders, lozenges (including liquid-
filled), chews, multi-and nano-
particulates, gels, films (including muco- adhesive), ovules, sprays and
liquid formulations.
Liquid formulations include suspensions, solutions, syrups and elixirs. Such
formulations may be
employed as fillers in soft or hard capsules and typically comprise a carrier,
for example, water, ethanol,
23
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
propylene glycol, methylcellulose, or a suitable oil, and one or more
emulsifying agents and/or
suspending agents. Liquid formulations may also be prepared by the
reconstitution of a solid, for
example, from a sachet.
The compounds of the invention may also be used in fast-dissolving, fast-
disintegrating dosage forms
such as those described in Expert Opinion in Therapeutic Patents, 11(6), 981-
986 by Liang and Chen
(2001).
A typical tablet may be prepared using standard processes known to a
formulation chemist, for example,
by direct compression, granulation (dry, wet, or melt), melt congealing, or
extrusion. The tablet
formulation may comprise one or more layers and may be coated or uncoated.
Examples of excipients suitable for oral administration include carriers, for
example, cellulose, calcium
carbonate, dibasic calcium phosphate, mannitol and sodium citrate, granulation
binders, for example,
polyvinylpyrrolidine, hydroxypropylcellulose, hydroxypropylmethylcellulose and
gelatin,
disintegrants, for example, sodium starch glycolat and silicates, lubricating
agents, for example,
magnesium stearate and stearic acid, wetting agents, for example, sodium
lauryl sulfate, preservatives,
anti-oxidants, flavours and colourants.
Solid formulations for oral administration may be formulated to be immediate
and/or modified release.
Modified release formulations include delayed-, sustained-, pulsed-,
controlled dual-, targeted and
programmed release. Details of suitable modified release technologies such as
high energy dispersions,
osmotic and coated particles are to be found in Verma et al, Pharmaceutical
Technology On-line, 25 (2),
.. 1-14 (2001). Other modified release formulations are described in US Patent
No. 6,106,864.
Parenteral Administration
The compounds of the invention may also be administered directly into the
blood stream, into muscle,
or into an internal organ. Suitable means for parenteral administration
include intravenous, intraarterial,
intraperitoneal, intrathecal, intraventricular, intraurethral, intrasternal,
intracranial, intramuscular and
subcutaneous. Suitable devices for parenteral administration include needle
(including microneedle)
injectors, needle-free injectors and infusion techniques.
Parenteral formulations are typically aqueous solutions which may contain
excipients such as salts,
carbohydrates and buffering agents (preferably to a pH of from 3 to 9), but,
for some applications, they
may be more suitably formulated as a sterile non-aqueous solution or as a
dried form to be used in
conjunction with a suitable vehicle such as sterile, pyrogen-free water.
The preparation of parenteral formulations under sterile conditions, for
example, by lyophilisation, may
readily be accomplished using standard pharmaceutical techniques well known to
those skilled in the
art.
24
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
The solubility of compounds of formula (I) used in the preparation of
parenteral solutions may be
increased by suitable processing, for example, the use of high energy spray-
dried dispersions and/or by
the use of appropriate formulation techniques, such as the use of solubility-
enhancing agents.
Formulations for parenteral administration may be formulated to be immediate
and/or modified release.
Modified release formulations include delayed, sustained, pulsed, controlled
dual, targeted and
programmed release.
Pharmaceutical compositions of the present invention also include compositions
and methods known
in the art for bypassing the blood brain barrier or can be injected directly
into the brain. Suitable areas
for injection include the cerebral cortex, cerebellum, midbrain, brainstem,
hypothalamus, spinal cord
and ventricular tissue, and areas of the PNS including the carotid body and
the adrenal medulla.
Dosage
The magnitude of an effective dose of a compound will, of course, vary with
the nature of the severity
of the condition to be treated and the route of administration. The selection
of appropriate dosages is
within the remit of the physician. The daily dose range is about 10 jig to
about 100 mg per kg body
weight of a human and non-human animal and in general may be around 10 jig to
30 mg per kg body
weight per dose. The above dose may be given from one to three times per day.
For example, oral administration may require a total daily dose of from 5 mg
to 1000 mg, such as from
5 to 500 mg, while an intravenous dose may only require from 0.01 to 30 mg/kg
body weight, such as
from 0.1 to 10 mg/kg, more preferably from 0.1 to 1 mg/kg body weight. The
total daily dose may be
administered in single or divided doses.
The skilled person will also appreciate that, in the treatment or prevention
of certain conditions,
compounds of the invention may be taken as a single dose on an "as required"
basis (i.e. as needed or
desired).
Synthetic methodologies
Compounds of formula (I) may be prepared using methods as described below in
the general reaction
schemes and the representative examples. Where appropriate, the individual
transformations within a
scheme may be completed in a different order. The invention is illustrated by
the following non-limiting
examples in which the following abbreviations and definitions are used.
Compounds were characterised
by liquid chromatography-mass spectroscopy (LCMS) or II-1 NMR or both.
According to a further aspect, the present invention provides a process for
the preparation of a
compound of formula (I) comprising deprotection of the compound of formula
(III) using standard
methods to give amine (II) which may then be reacted with cyanogen bromide to
give the corresponding
compound of formula (I):
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
N)fo
(C) N...._
IN.....õ...--\
N c.................(NH N C _ ...,....(N-
PG
CN (II) CH3 CN (III) CH3
wherein PG is a protecting group.
In a further aspect, the present invention provides a compound, which is
selected from formulae (II)
and (III), wherein PG is a protecting group, or a salt of said compound.
In a preferred embodiment, the present invention provides a compound, which is
selected from formulae
(IA) and (IIIA):
....TN -0 .----- N 0
1
H H
Z------0 N Z--------O
I (____:-
........ca.....1-)N ?
N¨PG 3a N 3a
i ,4
(3aR,4R,6aR) (3aR,4R,6aR) %al 1
uH3... , ,
3
(IA) (IIIA)
wherein PG is a protecting group, or a salt of said compound.
According to a further aspect, the present invention provides a process for
the preparation of a
compound of formula (III) comprising oxidation of the compound of formula (IV)
using standard
methods, such as with m-chloroperbenzoic acid, to give N-oxide (V) which may
then be reacted with
trimethylsilyl cyanide and dimethylcarbamoyl chloride to give the
corresponding compound of
formula (III):
az( )f(31
0
1.....
N (....õ....N-PG N < N-PG
-0
(Iv) CH3 (v) CH3
wherein PG is a protecting group.
In a further aspect, the present invention provides a compound, which is
selected from formulae (IV)
and (V), wherein PG is a protecting group, or a salt of said compound.
In a preferred embodiment, the present invention provides a compound, which is
selected from formulae
(IVA) and (VA):
26
CA 03186148 2022-12-05
WO 2021/249909 PCT/EP2021/065112
N N
1
H H
C:
,---------0 N Z---------0
../..--\¨PG I K N-
......z........¨\ _:)N¨PG
3a
.,4
r1 --,-. .::.; .-.. ,
,H3 113
(3aR,4R,6aR) U (3aR,4R,6aR) ,=
(IVA) (VA)
wherein PG is a protecting group, or a salt of said compound.
Protecting groups are preferably selected from tert-butyloxycarbonyl (BOC),
benzyloxycarbonyl (Cbz),
p-methoxybenzyl carbonyl (MeOZ), 9-fluorenylmethyloxycarbonyl (Fmoc), acetyl
(Ac), benzoyl (Bz),
5 benzyl (Bn), carbamate, p-methoxybenzyl (PMB), 3,4-dimethoxybenzyl
(DMPM), p-methoxyphenyl
(PMP), tosyl (Ts), trichloroethoxycarbonyl (Troc), 4-nitrobenzenesulfonyl
(Nosyl) and
2-nitrophenylsulfenyl (Nps). Most preferred are BOC and Cbz.
Abbreviations
br s broad singlet (NMR signal) Me0H methanol
CO carbon monoxide min minute(s)
d doublet (NMR signal) MsC1 methanesulfonyl chloride
dba dibenzylacetone N2 nitrogen
dibenzoyl-L-tartaric acid
(L)-DBTA NMP N-methylpyrrolidone
monohydrate
DCM dichloromethane p-TSA 4-toluenesulfonic acid
DMF NN-dimethylformamide rac racemic
DMSO dimethylsulfoxide rt room temperature
d.r. diastereomeric ratio Rf retention factor
e.e. enantiomeric excess s singlet (NMR signal)
ES electrospray SFC supercritical fluid
chromatogaphy
Et0Ac ethyl acetate 50C12 thionyl chloride
h hour(s) TBD 1,5,7-
triazabicyclo[4.4.01dec-5-ene
H2 hydrogen TEA triethylamine
high performance liquid
HPLC TFA trifluoroacetic acid
chromatography
IPA propan-2-ol THF tetrahydrofuran
liquid chromatography ¨ mass
LCMS TMSCN trimethylsilyl cyanide
spectrometry
m multiplet (NMR signal) vol volumes
MeCN acetonitrile
27
CA 03186148 2022-12-05
WO 2021/249909 PCT/EP2021/065112
LCMS / HPLC / SFC Methods
Method C
Mobile (A) 2 mM Ammonium acetate & 0.1% formic acid in water
phase (B) 0.1% Formic acid in acetonitrile
Instrument Waters ACQUITY H Class with PDA and SQ Detector
Column BEH C18 (50 mm x 2.1 mm) 1.7 um
Flow rate 0.550 mL/min
Column oven temperature Ambient
Run time 3.0 min
Gradient
TIME Flow Rate
% A % B
(min) (mL/min)
0.01 0.55 98 2
0.30 0.55 98 2
0.60 0.55 50 50
1.10 0.55 25 75
2.00 0.60 0 100
2.70 0.60 0 100
2.71 0.55 98 2
3.00 0.55 98 2
Method Cl
Mobile (A) 2 mM Ammonium acetate & 0.1% formic acid in water
phase (B) 0.1% Formic acid in acetonitrile
Instrument Waters ACQUITY UPLC H Class with PDA and SQ detector
Column BEH C18 (50 mm x 2.1 mm) 1.7 um
Flow rate 0.550 mL/min
Column oven temperature Ambient
Run time 2.0 min
Gradient
TIME Flow Rate
% A % B
(min) (mL/min)
0.00 0.55 95 5
0.60 0.60 30 70
0.80 0.65 10 90
1.10 0.65 0 100
1.70 0.65 0 100
1.71 0.55 95 5
2.00 0.55 95 5
28
CA 03186148 2022-12-05
WO 2021/249909 PCT/EP2021/065112
Method E
Mobile (A) 0.1% v/v (30% v/v Aqueous ammonia) in water
phase (B) 100% Me0H
Instrument Waters e2695 HPLC with PDA detector
Column X-bridge C8 (250 x 4.6 mm), 5[Im
Column oven temperature 45 C
Flow rate 1.0 mL/ min
Run time 45 min
Gradient
TIME Flow Rate
% A % B
(min) (mL/min)
0.0 1.0 10 90
5.00 1.0 20 80
10.00 1.0 30 70
30.00 1.0 30 70
35.00 1.0 60 40
35.01 1.0 90 10
40.00 1.0 90 10
40.01 1.0 10 90
45.00 1.0 10 90
Method F
Mobile (A) 10 mM Ammonium acetate in water
phase (B) 100 % Acetonitrile
Agilent 1290 Infinity RRLC attached with Agilent 6120
Instrument
mass detector and PDA detector
Column YMC TRIART, C18 (150 mm x 4.6 mm), 5 [tm
Flow rate 1.0 mL/min
Column oven temperature Ambient
Run time 12.0 min
Gradient
TIME Flow Rate
% A % B
(min) (mL/min)
0.01 1.0 90 10
5.00 1.0 10 90
7.00 1.0 0 100
11.00 1.0 0 100
11.01 1.0 90 10
12.00 1.0 90 10
29
CA 03186148 2022-12-05
WO 2021/249909 PCT/EP2021/065112
Method H
Mobile (A) 5 mM Ammonium bicarbonate in water
phase (B) 100% Acetonitrile
Shimadzu Nexera UFLC with 2020 single quadrupole
Instrument
mass detector
Column Waters X-Bridge C18 (50 x 4.6 mm) 3.5 um
Column oven temperature Ambient
Flow rate 1.0 mLimin
Run time 8.0 min
Gradient
TIME Flow Rate
% A % B
(min) (mLimin)
0.01 1.0 95 5
3.50 1.0 10 90
4.50 1.0 5 95
6.00 1.0 5 95
6.01 1.0 95 5
8.00 1.0 95 5
Method H1
Mobile (A) 5 mM Ammonium bicarbonate in water
phase (B) 100% Acetonitrile
Shimadzu Nexera UFLC with 2020 single quadrupole mass
Instrument
detector
Column Waters X-Bridge C18 (50 x 4.6 mm) 3.5 um
Column oven temperature Ambient
Flow rate 1.0 mLimin
Run time 6.0 min
Gradient
TIME Flow Rate
% A % B
(min) (mLimin)
0.01 1.0 95 5
2.80 1.0 15 85
3.50 1.0 5 95
5.00 1.0 5 95
5.01 1.0 95 5
6.00 1.0 95 5
CA 03186148 2022-12-05
WO 2021/249909 PCT/EP2021/065112
Method H3
Mobile (A) 5 mM Ammonium bicarbonate in water
phase (B) 100% Acetonitrile
Instrument Shimadzu Nexera high pressure UHPLC and LCMS-2020
Column Waters X-Bridge C18 (50 x 4.6 mm), 3.5 um
Column oven temperature Ambient
Flow rate 1.0 mL/min
Run time 6.0 min
Gradient
TIME Flow Rate
% A % B
(min) (mL/min)
0.01 1.0 95 5
2.80 1.0 15 85
3.50 1.0 5 95
5.00 1.0 5 95
5.01 1.0 95 5
6.00 1.0 95 5
Method X
Mobile (A) 10 mM Ammonium acetate & 0.1% formic acid in water
phase (B) 0.1% Formic acid in
acetonitrile
Agilent 1290 Infinity RRLC attached with Agilent 6120
Instrument
mass detector and PDA detector
Column YMC-Pack ODS-AQ (250 x 4.6 mm), 5 um
Flow rate 1.0 mL/min
Column oven temperature Ambient
Run time 30.0 min
Gradient
TIME Flow Rate
% A % B
(min) (mL/min)
0.01 1.0 90 10
10.00 1.0 60 40
20.00 1.0 20 80
25.00 1.0 0 100
28.00 1.0 0 100
28.01 1.0 90 10
30.00 1.0 90 10
31
CA 03186148 2022-12-05
WO 2021/249909 PCT/EP2021/065112
Method X2
Mobile (A) 0.1% v/v (30% v/v Aqueous ammonia) in water
Phase (B) 0.1% v/v (30% v/v Aqueous ammonia) in acetonitrile
Instrument Waters e2695 HPLC with PDA detector
Column X-bridge C8 (250 x 4.6 mm), 5 [tm
Flow rate 1.0 mL/min
Run time 40.0 min
Gradient
TIME Flow Rate
% A % B
(min) (mL/min)
0.0 1.0 95 5
5.00 1.0 95 5
10.00 1.0 70 30
15.00 1.0 70 30
25.00 1.0 40 60
30.00 1.0 10 90
35.00 1.0 10 90
35.01 1.0 95 5
Method Y4
Mobile (A) Liquid carbon dioxide
Phase (B) 0.1% Diethylamine in propan-2-ol : acetonitrile (50:50)
Instrument Waters SFC Investigator and PDA detector
Column Chiralpak IH (250 x 4.6 mm), 5 [tm
Flow rate 4.0 mL/min
Run time 10.0 min
Gradient
TIME Flow Rate
% B start Bend
(min) (mL/min)
0 to 5 4.0 5 50
to 10 4.0 50 50
32
CA 03186148 2022-12-05
WO 2021/249909 PCT/EP2021/065112
Method Yll
Mobile (A) 0.1% Diethylamine in n-hexane
Phase (B) 0.1% Diethylamine in propan-2-ol : acetonitrile
(70-30)
Instrument Agilent 1260 Series HPLC and PDA detector
Column Chiralpak IC (250 x 4.6 mm), 5 [tm
Flow rate 1.0 mLimin
Run time 25.0 min
Gradient
TIME Flow Rate
% A % B
(min) (mLimin)
0.01 1.0 80 20
5.00 1.0 50 50
10.00 1.0 30 70
20.00 1.0 30 70
20.01 1.0 80 20
25.00 1.0 80 20
Method Y13
Mobile (A) Liquid carbon dioxide
Phase (B) 0.1% Diethylamine in propan-2-ol : acetonitrile
(50:50)
Instrument Waters SFC Investigator and PDA detector
Column Chiralpak IC (250 x 4.6 mm), 5 [tm
Flow rate 4.0 mLimin
Run time 8.0 min
Gradient
TIME Flow Rate
% B start % B end
(min) (mLimin)
0 to 5 4.0 5 50
to 8 4.0 50 50
33
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
Method Y15
Mobile (A) 0.1% Diethylamine in n-hexane
Phase (B) 0.1% Diethylamine in propan-2-ol : acetonitrile (70:30)
Instrument Agilent 1260 series HPLC and PDA detector
Column Chiralpak IC (250 x 4.6 mm), 5 [tm
Flow rate 1.0 mL/min
Run time 25.0 min
Gradient
TIME Flow Rate
% A % B
(min) (mL/min)
0.01 1.0 80 20
5.00 1.0 45 55
10.00 1.0 30 70
15.00 1.0 30 70
20.00 1.0 80 20
25.00 1.0 80 20
Method Y17
Mobile (A) 0.1% Diethylamine
in methanol
Phase (B) 0.1% Diethylamine in acetonitrile
Instrument Agilent 1260 series HPLC and PDA detector
Column Chiralpak IG (250 x 4.6 mm), 5 [tm
Flow rate 1.0 mL/min
Run time 20.0 min
Isocratic
TIME Flow Rate
% A % B
(min) (mL/min)
0.01 20.00 50 50
Method Y20
Mobile (A) Liquid carbon dioxide
Phase (B) 0.1% Diethylamine in propan-2-ol : acetonitrile (50:50)
Instrument Waters SFC Investigator and PDA detector
Column Chiralpak IH (250 x 4.6 mm), 5 [tm
Flow rate 4.0 mL/min
Run time 9.0 min
Gradient
TIME Flow Rate
% B start % B end
(min) (mL/min)
0 to 5 4.0 5 50
to 9 4.0 50 50
34
CA 03186148 2022-12-05
WO 2021/249909 PCT/EP2021/065112
Method Y22
Mobile (A) Liquid carbon dioxide
Phase (B) 0.2% NH4OH in
methanol
Instrument Waters SFC Investigator with PDA Detector
Column Chiralpak IC (250 x 4.6 mm), 5 um
Flow rate 4.0 mL/min
Run time 10 min.
Gradient
TIME Flow Rate
% B start Bend
(min) (mL/min)
0 to 5 4.0 5 50
to 10 4.0 50 50
Method Y23
Mobile (A) 0.1% Diethylamine in methanol
Phase (B) Liquid carbon dioxide
Instrument Agilent 1100 series HPLC with PDA detector
Column Chiralpak IG (250 x 4.6 mm), 5 um
Flow rate 1.0 mL/ min
Run time 8 min.
Isocratic
TIME Flow Rate
% A % B
(min) (mL/min)
0 to 8 1.0 100 0
Method Y24
Mobile (A) Liquid carbon dioxide
Phase (B) 0.1% Diethylamine in methanol : acetonitrile (50:50)
Instrument Waters SFC Investigator with PDA detector
Column Chiralpak AD-H (250 x 4.6 mm), 5 um
Flow rate 4.0 mL/ min
Run time 14 min
Gradient
TIME Flow Rate
% B start Bend
(min) (mL/min)
0 to 5 4.0 5 50
5 to 9 4.0 50 50
CA 03186148 2022-12-05
WO 2021/249909 PCT/EP2021/065112
Method Y25
Mobile (A) Liquid carbon dioxide
Phase (B) 0.1% Diethylamine in
propan-2-ol : acetonitrile (50:50)
Instrument Waters SFC Investigator with PDA detector
Column Chiralpak AD-H (250 x 4.6 mm), 5 um
Flow rate 4.0 mL/ min
Run time 15 min
Gradient
TIME Flow Rate
% B start % B end
(min) (mL/min)
0 to 5 4.0 5 50
to 10 4.0 50 50
Method Y26
Mobile (A) 0.1% Diethylamine in methanol
Phase (B) Liquid carbon dioxide
Instrument Agilent 1100 series HPLC with PDA detector
Column Chiralpak IG (250 x 4.6 mm), 5 um
Flow rate 1.0 mL/ min
Run time 9 min.
Isocratic
TIME Flow Rate
% A % B
(min) (mL/min)
0 to 9 1.0 100 0
Method Y28
Mobile (A) 0.1% Diethylamine in n-hexane
Phase (B) 0.1% Diethylamine in
propan-2-ol : acetonitrile (70:30)
Instrument Agilent
1260 infinity series HPLC with PDA detector
Column Chiralpak IC (250 x 4.6 mm), 5 um
Flow rate 1.0 mL/min
Run time 40.0 min
Isocratic
TIME Flow Rate
% A % B
(min) (mL/min)
0.01 to 40 1.0 60 40
36
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
Intermediate A
Ethyl 5-(pyridin-4-yl)oxazole-2-carboxylate
0
01
HN-Boc ________________________ 0 0 \-0 o - __________________ rrN
)-Br ____ N\ ____________________________ N
\- \ 0
(I) (ii)
.HCI HN-Boc H2N .TFA 0
(i) i-PrMgC1, THF, rt; (ii) TFA, DCM, 0 C to rt; (iii) TEA, DCM, 0 C to rt.
Step (i)
tert-Butyl (2-oxo-2-(pyridin-4-yl)ethyl)carbamate
4-Bromopyridine hydrochloride (CAS 19524-06-2, from CombiBlocks, 8.0 g, 41.2
mmol) was treated
with 5% aqueous Na2CO3 (300 mL) and was extracted with DCM (2 x 100 mL). The
combined organic
phases were dried over Na2SO4 and concentrated under reduced pressure. The
residue was immediately
dissolved in dry THF (50 mL) and isopropylmagnesium chloride (2 M in THF,
20.57 mL, 41.2 mmol)
was added dropwise at rt under N2. The resulting dark solution was stirred at
rt for 1.5 h, during which
time a precipitate formed. Meanwhile, to a stirred suspension of tert-butyl-(2-
(me thoxy(methyl)amino)-
2-oxoethyl)carbamate (7.1 g, 32.9 mmol) in THF (50 mL) was added
isopropylmagnesium chloride
(2 M in THF, 16.4 mL, 32.9 mmol) dropwise at 0 C. The solution was stirred
for 10 min before being
.. added dropwise at rt to the pyridyl Grignard. The mixture was stirred at rt
for 16 h then poured into
water (200 mL) and extracted with Et0Ac (2 x 200 mL). The combined organic
phases were dried over
Na2SO4 and concentrated under reduced pressure. The residue was purified by
column chromatography
(30% Et0Ac in n-hexanes) to obtain tert-butyl (2-oxo-2-(pyridin-4-
yl)ethyl)carbamate (4.8 g,
20.3 mmol, 49% yield).
LCMS: Method C, 1.40 min, MS: ES+ 237.1; IFINMR (400 MHz, CDC13) 6 ppm: 8.88 -
8.89 (d, J =
5.6 Hz, 2H), 7.77 - 7.79 (d, J= 6.8 Hz, 2H), 5.49 (br s, 1H), 4.69 - 4.71 (d,
J= 4.4 Hz, 2H), 1.52 (s,
9H).
Step (ii)
2-Amino-1-(pyridin-4-yl)ethan-l-one TFA salt
To a stirred solution of tert-butyl (2-oxo-2-(pyridin-4-yl)ethyl)carbamate
(4.8 g, 20.34 mmol) in DCM
(50 mL) was added TFA (2.4 mL, 5 vol) dropwise at 0 C. The mixture was slowly
warmed to rt and
stirred for 2 h, then concentrated under reduced pressure with DCM (3 x 100
mL) to afford 2-amino-1-
(pyridin-4-ypethan-1-one TFA salt (7.0 g, quantitative yield).
LCMS: Method C, 0.29 min, MS: ES+ 136.96; 1HNMR (400 MHz, DMSO-d6) 6 ppm: 8.91
- 8.93 (d,
J= 6.0 Hz, 2H), 8.36 (br s, 3H), 7.92 - 7.94 (d, J = 6.0 Hz, 2H), 4.68 (t, J =
5.2 Hz, 2H).
Step (iii)
Ethyl 5-(pyridin-4-yl)oxazole-2-carboxylate
37
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
This reaction was performed in duplicate. To a stirred solution of 2-amino-1-
(pyridin-4-ypethan- 1-one
TFA salt (3.0 g, 12 mmol) in DCM (80 mL) was added TEA (3.75 g, 5.17 mL, 37.2
mmol) dropwise at
rt. Ethyl chlorooxalate (1.63 g, 1.33 mL, 12 mmol) was added dropwise at 0 C.
The mixture was
slowly warmed to rt and stirred for 24 h. The two batches were combined and
poured into water
(200 mL) and extracted with DCM (2 x 200 mL). The combined organic phases were
dried over Na2SO4
and concentrated under reduced pressure. The residue was purified by column
chromatography (40%
Et0Ac in n-hexanes) to obtain ethyl 5-(pyridin-4-yl)oxazole-2-carboxylate
(0.45 g, 2.06 mmol, 10%
yield over 2 steps).
LCMS: Method C, 1.29 min, MS: ES+ 219.25; 1HNMR (400 MHz, DMSO-d6) 6 ppm: 8.74
- 8.75 (d,
J = 5.6 Hz, 2H), 8.29 (s, 1H), 7.79 - 7.80 (d, J = 6.0 Hz, 2H), 4.40-4.45 (q,
J= 7.2, Hz, 2H), 1.37 (t, J=
6.8 Hz, 3H).
Intermediate B
rac-tert-Butyl-(3aS,4R,6aR)-4-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-
carboxylate
¨0 ¨0
¨0 0 ____________________________________ ) 0 //¨\
¨0 NH2 ¨0
0 0
edN4 N-4
NH.HCI
NH.HCI
(iv) N," OEt N OEt (v) N'''
Bn Bn Bn Bn
(3aR,6aR) AND (3aS,6aS) (3aR,6aR) AND (3aS,6aS)
E.=
-
N Boc N-Boc N-Boc
(vi) (vii)
Bn Br Br Br
(3aR,6aR) AND (3aS,6aS) (3aR,4S,6aR)
(3aR,4R,6aR)
AND enantiomer AND enantiomer
Fraction 1 Fraction 2
Fraction 2 N¨Boc
(viii) (3aS,4R,6aR)
AND enantiomer
(i) Et0C(0)C1, NaOH, DCM, 0 C to rt; (ii) NaH, DMF, 3-chlorobut-1-ene, 0 C
to rt; (iii) HCO2H,
0 C then 100 C; (iv) N-benzylglycine, toluene, 110 C; (v) conc. HC1, 110
C; (vi) (BOC)20, TEA,
4-dimethylaminopyridine, DCM, 0 C to rt; (vii) chromatographic separation;
(viii) Pd(OH)2, Me0H, Hz, rt.
Step (i)
Ethyl (2, 2-dimethoxyethyl)carbamate
To a stirred solution of 2,2-dimethoxyethan- 1-amine (CAS 22483-09-6, from
Combi-blocks, 12.5 g,
118.9 mmol) in DCM (100 mL) was added aqueous sodium hydroxide (5.2 g, 130.8
mmol) solution in
38
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
water (31 mL) dropwise at 0 C. Ethyl chloroformate (14.2 g, 130.8 mmol) was
added and the mixture
was stirred at rt for 16 h. This mixture and a duplicate reaction mixture were
poured into water (500 mL)
and extracted with DCM (3 x 500 mL). The combined organic phases were dried
over anhydrous
Na2SO4, filtered and concentrated under reduced pressure to yield ethyl (2,2-
dimethoxyethyl)carbamate
(36.5 g, quantitative yield).
1HNMR (400 MHz, DMSO-d6) 6 ppm: 7.15 (s, 1H), 4.34 (t, J= 5.2 Hz, 1H), 3.98
(q, J = 7.2 Hz, 2H),
3.24 (s, 6H), 3.05 (t, J = 5.6 Hz, 2H), 1.15 (t, J= 7.2 Hz, 3H).
Step (ii)
Ethyl but-3-en-2-yl-(2,2-dimethoxyethyl)carbamate
To a stirred solution of ethyl (2,2-dimethoxyethyl)carbamate (12.1 g, 68.3
mmol) in DMF (50 mL) was
added NaH (60 % in mineral oil, 6.84 g, 170.9 mmol) in portions over 2 h at 0
C. The mixture was
stirred at 0 C for 2 h, then 3-chlorobut-1-ene (7.6 mL, 75.2 mmol) was added
and the mixture stirred
at rt for 20 h. This mixture and two duplicate reaction mixtures were quenched
into ice-cold water
(300 mL) and extracted with Et0Ac (3 x 500 mL). The combined organic phases
were washed with
cold water (3 x 150 mL) and brine (2 x 150 mL). The organic phase was dried
over anhydrous Na2SO4
and concentrated under reduced pressure. The residue was purified by column
chromatography (basic
aluminium oxide, 5% Et0Ac in n-hexanes) to yield ethyl but-3-en-2-y1-(2,2-
dimethoxyethyl)carbamate
(15.5 g, 67.0 mmol, 28% yield over two steps).
1HNMR (400 MHz, DMSO-d6) 6 ppm: 5.88 - 5.94 (m, 1 H), 5.08 - 5.11 (m, 2H),
4.41 - 4.48 (m, 2H),
4.05 - 4.06 (m, 2H), 3.18 - 3.35 (m, 8H), 1.18 - 1.24 (m, 6H).
Step (iii)
Ethyl but-3-en-2-yl(2-oxoethyl)carbamate
To a stirred solution of ethyl but-3-en-2-y1(2,2-dimethoxyethyl)carbamate
(15.5 g, 67.0 mmol) was
added formic acid (36 mL) dropwise at 0 C. The mixture was heated at 100 C
for 2 h then cooled to
rt, poured into ice-cold water (200 mL) and extracted with Et0Ac (3 x 300 mL).
The combined organic
phases were washed with saturated NaHCO3 solution (3 x 100 mL). The organic
phase was dried over
anhydrous Na2SO4 and concentrated under reduced pressure to yield ethyl but-3-
en-2-y1-(2-
oxoethyl)carbamate (11.3 g, 61.1 mmol, 91% yield).
1HNMR (400 MHz, DMSO-d6) 6 ppm: 9.47 (s, 1H), 5.75 - 5.85 (m, 1H), 5.10 - 5.15
(m, 2H), 4.65 -
4.77(m, 1H), 3.80 - 4.07 (m, 4H), 1.10- 1.18 (m, 6H).
Step (iv)
rac-Ethyl-(3aR,6aR)-1-benzyl-4-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-
carboxylate
To a stirred solution of ethyl but-3-en-2-y1-(2-oxoethyl)carbamate (4.7 g,
25.4 mmol) in toluene
(100 mL) was added N-benzylglycine (CAS 17136-36-6, from Combi-blocks, 4.2 g,
25.4 mmol) at rt.
The mixture was heated at 110 C for 16 h then concentrated under reduced
pressure. The residue was
purified by column chromatography (basic aluminium oxide, 7% Et0Ac in n-
hexanes) to yield
39
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
rac-ethyl (3aR,6aR)-1-benzy1-4-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-
carboxylate (3.2 g,
11.1 mmol, 43% yield).
LCMS: Method C, 1.33 min, two broad peaks merged, no baseline separation of
the two diastereomers,
MS: ES+ 289.3.
Step (v)
rac-(3aR,6aR)-1-Benzy1-4-methyloctahydropyrrolo[3,4-b]pyrrole HCl salt
A stirred solution of rac-ethyl (3aR,6aR)-1-benzy1-4-
methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-
carboxylate (3.2 g, 11.1 mmol) in concentrated HC1 (40 mL, 12.5 vol) was
heated at 100 C for 16 h.
The mixture was cooled to rt and concentrated under reduced pressure to yield
rac-(3aR, 6aR)-1-benzyl-
4-methyloctahydropyrrolo[3,4-b]pyrrole HC1 salt (3.72 g, quantitative yield).
LCMS: Method F, 4.45 min and 4.92 min, two diastereomers, MS: ES+ 217.3.
Step (vi)
rac-tert-Butyl-(3aR,6aR)-1-benzy1-4-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-
carboxylate
To a stirred solution of rac-(3aR,6aR)-1-benzy1-4-methyloctahydropyrrolo[3,4-
b]pyrrole HC1 salt
(3.7 g, 14.65 mmol) in DCM (40 mL) were added triethylamine (10.3 mL, 73.5
mmol),
4-dimethylaminopyridine (0.09 g, 0.73 mmol) and di-tert-butyl dicarbonate
(3.83 g, 17.58 mmol) at
0 C. The mixture was allowed to warm to rt and stirred for 5 h, then poured
into water (100 mL) and
extracted with DCM (2 x 150 mL). The combined organic phases were dried over
anhydrous Na2SO4
and concentrated under reduced pressure. The residue was carried through the
chromatographic
separation in Step (vii).
Step (vii)
rac-tert-Butyl-(3aR,4R,6aR)-1-benzy1-4-methylhexahydropyrrolo[3,4-b]pyrrole-
5(1H)-carboxylate
(major isomer) and
rac-tert-Butyl-(3aR,4S,6aR)-1-benzy1-4-methylhexahydropyrrolo[3,4-b]pyrrole-
5(1H)-carboxylate
(minor isomer)
The residue from Step (vi) was purified by column chromatography (basic
aluminium oxide, 2% Et0Ac
in n-hexanes) to yield two separate fractions in a 4.2: 1 ratio.
The first eluting fraction, Fraction 1, rac-tert-butyl-(3aR, 4S, 6aR)-1-benzy1-
4-
methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxylate (minor isomer, 0.50 g)
was isolated as a
colourless oil. TLC: Rf 0.5 (30% Et0Ac/n-hexanes).
LCMS: Method C, 1.46 min, MS: ES+ 317.4 and Method X, 13.70 min, MS: ES+
317.3.
The second eluting fraction, Fraction 2, rac-tert-butyl-(3aR,4R,6aR)-1-benzy1-
4-
methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxylate (major isomer, 2.10 g,
6.63 mmol, 45%
yield) was isolated as a colourless oil. TLC: Rf 0.4 (30% Et0Ac / n-hexanes).
LCMS: Method C, 1.46 min, MS: ES+ 317.4 and Method X, 13.37 min, MS: ES+
317.3; d.r. 99:1 by
Method X.
CA 03186148 2022-12-05
WO 2021/249909 PCT/EP2021/065112
Fraction 2 was carried forward to Step (viii).
Step (viii)
rac-tert-Butyl-(3aS,4R,6aR)-4-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-
carboxylate
To a stirred solution of rac-tert-butyl (3aR,4R,6aR)-1-benzy1-4-
methylhexahydropyrrolo[3,4-b]-
pyrrole-5(1H)-carboxylate (Fraction 2, major isomer, 0.50 g, 1.58 mmol) in
Me0H (10 mL) was added
20% Pd(OH)2 (50% moisture, 250 mg, 50% w/w) and purged with H2 gas for 4 h at
rt. The mixture
was filtered through a celite bed, washed with Me0H (50 mL) and concentrated
under reduced pressure
to yield rac-tert-butyl-(3aS,4R,6aR)-4-methylhexahydropyrrolo [3 ,4-b] pyrrole
-5 (1H)-carboxylate (0.33
g, 1.46 mmol, 92% yield).
LCMS: Method C, 1.29 min, MS: ES+ 227.32.
Intermediate C
tert-butyl-(3aS,4R,6aR)-4-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-
carboxylate
or
NH2.1-1C1 HN
= 2 (C)
Et0 CN
0
0 7 0
0 0 0
Et0
2
CN 2 (C)
Et0 CN 2 C)
HO
Et0 CN (
, H2C
(R) (iv) (R) (v) aR) (vi)
EtO2CN Bn, (iR) NCO2Et Bn, (s)C11CO2Et
(R) (R) (s) JR)
(vii) AND
(viii)
Bn, (R) NH
Bn, (R) NH 0 OBz
N (R) JR) AND N (s) JR) N (R) JR) )..r0H
HO
(ix)
2 OBz 0
(R) NBoc
Bn ,N (R) N.,13(Ro) c
HN JR)
e.e. 99.6%
(x) dr. 99.5 : 0.5 kxli
Step (i)
Methyl (2,2-dimethoxyethyl)-D-alaninate
To a stirred mixture of 2,2-dimethoxyacetaldehyde (97.01 g, 931.89 mmol) in
Me0H (100 mL) was
added methyl D-alaninate HC1 (100.0 g, 716.84 mmol) at 0 C. The mixture was
stirred at rt for 2 h.
Sodium cyanoborohydride (58.52 g, 931.89 mmol) was added in portions under N2
atmosphere at 0 C
and stirred at rt for 18 h. The mixture was filtered over Celite and washed
with Me0H (2 x 200 mL).
The filtrate was concentrated under reduced pressure and the residue was
poured into water (1000 mL)
and was extracted with DCM (2 x 1000 mL). The combined organic phases were
dried over sodium
41
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
sulfate and concentrated under reduced pressure at 40 C to provide methyl
(2,2-dimethoxyethyl)-D-
alaninate as a pale yellow oil (135.0 g, 705.95 mmol, 98% yield).
'H NMR (400 MHz, CDC13) 6 ppm: 4.41 - 4.54 (m, 1H), 3.75 (s, 3H), 3.47 - 3.50
(m, 1H), 3.38 - 3.46
(m, 6H), 2.76 - 2.81 (m, 1H), 2.64 - 2.68 (m, 1H), 1.31- 1.35 (d, J= 7.2 Hz,
3H).
The method was repeated three times in an identical manner using methyl D-
alaninate HC1 (500 g,
1200 g and 1200 g scale) to provide the subtitle compound (respectively, 680
g, 1625 g and 1625 g).
Combined weight of all three batches: 4065 g, 21.25 mol.
Step (ii)
Methyl N-(2, 2-dime thoxyethyl)-N-(e thoxycarb ony1)-D-alaninate
To a stirred mixture of sodium bicarbonate (88.95 g, 1058 mmol) in water (810
mL) was added a
solution of methyl (2,2-dimethoxyethyl)-D-alaninate (135 g, 705.95 mmol) in
THF (810 mL) at rt.
Ethyl chloroformate (91.93 g, 847.14 mmol) was added to the cooled biphasic
solution (-5 to 5 C) and
the mixture was stirred at rt for 2 h. The mixture was poured into water (1.35
L) and extracted with
Et0Ac (2 x 675 mL). The combined organic phases were washed with saturated
solution of KHSO4
(675 mL), dried over sodium sulfate and concentrated under reduced pressure at
40 C to obtain methyl
N-(2,2-dimethoxyethyl)-N-(ethoxycarbony1)-D-alaninate as an oil (150.0 g,
569.71 mmol, 80% yield).
1H NMR (400 MHz, CDC13) 6 ppm: 4.52 (m, 2H), 4.15 - 4.27 (m, 2H), 3.78 (s,
3H), 3.40 - 3.63 (m,
9H), 1.50 - 1.52 (d, J= 6.8 Hz, 2H), 1.23 - 1.39 (m, 3H).
The method was repeated four times in an identical manner using methyl (2,2-
dimethoxyethyl)-D-
alaninate (680 g, 1000 g, 1000 g and 1250 g scale) to provide the subtitle
compound (respectively 775 g,
1360 g, 1365 g and 1375 g). Combined weight of all three batches: 5025 g,
19.09 mol.
Step (iii)
Ethyl (R)-(2, 2-di me thoxye thyl)(1 -hydroxypropan- 2-yl)carbamate
To a stirred mixture of methyl N-(2,2-dimethoxyethyl)-N-(ethoxycarbony1)-D-
alaninate (100 g,
379.8 mmol) in ethanol (1.8 L) and THF (200 mL) was added LiBH4 (2M in THF,
949.5 mL,
1899.04 mmol) dropwise at 0 C. The mixture was stirred at rt for 18 h, then
quenched by the addition
of a cold solution of ammonium chloride (50 g) in water (500 mL) twice and
concentrated under reduced
pressure to remove the more volatile organic solvent. The residue was taken up
in Et0Ac (500 mL).
The organic plase was separated, dried over sodium sulfate and concentrated
under reduced pressure at
40 C to obtain ethyl (R)-(2,2-dimethoxyethyl)(1-hydroxypropan-2-yl)carbamate
as an oil (72.0 g,
306.01 mmol, 81% yield).
1H NMR (400 MHz, CDC13) 6 ppm: 4.85 - 4.86 (m, 1H), 4.65 (m, 1H), 4.15 - 4.24
(m, 3H), 3.71 - 3.72
(m, 2H), 3.41 -3.56 (m, 6H), 3.14 -3.19 (m, 1H), 2.99 - 3.05 (m, 2H), 1.28 -
1.34 (m, 3H), 1.13 - 1.15
(m, 1H), 1.03 - 1.05 (m, 1H).
The method was repeated five times in an identical manner using methyl N-(2,2-
dimethoxyethyl)-N-
(ethoxycarbony1)-D-alaninate (500 g, 500 g ,1200 g, 1200 g and 1200 g scale)
to provide the subtitle
42
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
compound (respectively 336 g, 336 g, 929 g, 930 g and 930 g). Combined weight
of all three batches:
3533 g, 15.01 mol.
Step (iv)
Ethyl (R)-(2,2-dimethoxyethyl)(1-oxopropan-2-Acarbamate
To a stirred mixture of ethyl (R)-(2,2-dimethoxyethyl)(1-hydroxypropan-2-
yl)carbamate (400.0 g,
1700.1 mmol) in DCM : water (1.04 L, 1:1) were added NaHCO3 (428 g, 5100 mmol)
and TEMPO
(2.6 g, 17.0 mmol) at rt. A solution of sodium hypochlorite (1M Na0C1 solution
was freshly prepared
from solid Na0C1 : 5H20, 391.1 g, 2210.13 mmol, diluted with 4.98 L water) was
added to the biphasic
solution at 0 C. The mixture was warmed to rt and stirred for 18 h, then
quenched carefully with 10%
(w/v) aqueous sodium thiosulfate solution (2.8 L) and extracted with DCM (2 x
4.0 L). The organic
phase was dried over sodium sulfate and concentrated under reduced pressure at
40 C to obtain ethyl
(R)-(2,2-dimethoxyethyl)(1-hydroxypropan-2-yl)carbamate as an oil (360 g,
1543.3 mmol, 90.78%
yield).
1HNMR (400 MHz, CDC13) 6 ppm: 9.59 (s, 1H), 4.46 - 4.48 (m, 1H), 4.16 - 4.24
(m, 2H), 3.84 - 3.89
(m, 1H), 3.52 -3.56 (m, 1H), 3.42 - 3.47 (m, 6H), 3.30 - 3.40 (m, 1H), 1.38 -
1.41 (m, 3H), 1.22 - 1.34
(m, 3H).
The method was repeated three times in an identical manner using ethyl (R)-
(2,2-dimethoxyethyl)(1-
hydroxypropan-2-yl)carbamate (1100 g, 840 g and 1200 g) to provide the
subtitle compound
(respectively 1026 g, 820 g and 1020 g). Combined weight of all three batches:
3226 g, 13.83 mol.
Step (v)
Ethyl (R)-but-3-en-2-yl(2,2-dimethoxyethyl)carbamate
To a stirred mixture of methyltriphenylphosphonium bromide (137.7 g, 385.8
mmol) in THF (1.8 L)
was added KHMDS (1M in THF, 401.26 ml, 401.2 mmol) dropwise at 0 C. The
mixture was stirred
at rt for 1 h, then a solution of ethyl (R)-(2,2-dimethoxyethyl)(1-
hydroxypropan-2-yl)carbamate (72.0 g,
308.6 mmol) in THF (576 mL) was added dropwise at -78 C under N2 atmosphere.
The mixture was
stirred at rt for 18 h then quenched with Me0H (2.2 mL) and stirred for 30 min
at rt. The mixture was
concentrated, co-distilled with hexane (3 x 1500 mL), cooled to 0 C and
filtered to remove precipitated
MePPh20 and PPh30. The organic phase was concentrated, cooled, and re-
filtered. The resulting
filtrate was concentrated under reduced pressure at 40 C to obtain ethyl (R)-
but-3-en-2-y1(2,2-
dimethoxyethyl)carbamate (65 g, 1543.3 mmol, 91% yield) as a light brown oil.
1H NMR (400 MHz, CDC13) ppm: 6 5.92 -6.03 (m, 1H), 5.11 -5.16 (m, 1H), 4.52
(s, 2H), 4.17 - 4.23
(m, 2H), 3.45 (s, 6H), 3.27 (m, 2H), 2.67 -2.72 (m, 1H), 1.26 - 1.33 (m, 6H).
The method was repeated three times in an identical manner using ethyl (R)-
(2,2-dimethoxyethyl)(1-
hydroxypropan-2-yl)carbamate (735 g, 1417 g and 1020 g) to provide the
subtitle compound
(respectively 644 g, 1262 g and 860 g). Combined weight of all three batches:
2831 g, 12.24 mol.
43
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
Step (vi)
Ethyl (R)-but-3-en-2-y1(2-oxoethyl)carbamate
To a stirred mixture of ethyl (R)-but-3-en-2-y1(2,2-dimethoxyethyl)carbamate
(300.0 g, 1297.07 mmol)
in acetone (6.0 L) and water (600 mL) was added p-toluene sulfonic acid
monohydrate (78.9 g,
.. 415.06 mmol) at rt. The mixture was heated at 60 C for 18 h, allowed to
cool to rt and concentrated
under reduced pressure. The mixture was concentrated and the residue was
poured into saturated
NaHCO3 solution (1500 mL) and extracted with Et0Ac (2 x 1000 mL). The combined
organic phases
were dried over anhydrous Na2SO4, filtered and concentrated under reduced
pressure to obtain ethyl
(R)-but-3-en-2-y1(2-oxoethyl)carbamate as a pale yellow oil (230 g,
1242.5mmo1, 96% yield).
1HNMR (400 MHz, CDC13) 6 ppm: 9.55 (s, 1H), 5.79 - 5.86 (m, 1H), 5.05 - 5.25
(m, 2H), 5.00 - 5.05
(m, 1H), 4.12 -4.22 (m, 2H), 3.70 -3.92 (m, 2H), 1.24 - 1.31 (m, 6H).
The method was repeated three times in an identical manner using ethyl (R)-but-
3-en-2-y1(2,2-
dimethoxyethyl)carbamate (1020 g, 670 g and 860 g) to provide the subtitle
compound (respectively
795 g, 480 g, 605 g). Combined weight of all three batches: 2110 g, 11.39 mol.
Step (vii)
Ethyl (3aR,4R,6aR)-1-benzy1-4-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-
carboxylate, mixture
with ethyl (3aS,4R,6aS)-1-benzy1-4-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-
carboxylate
(70: 30 mixture of diastereomers)
In a 10 L round-bottomed flask, equipped with Dean-Stark apparatus, a mixture
of ethyl (R)-but-3-en-
2-y1-(2-oxoethyl)carbamate (200.0 g, 1079.7 mmol) in toluene (7.2 L, 36 vol)
was stirred at rt.
N-Benzylglycine (214.02 g, 1295.7 mmol) was added to the mixture, which was
then heated at 120 C
for 18 h, allowed to cool to rt and concentrated under reduced pressure. The
residue was poured in to
saturated NaHCO3 solution (2000 mL) and was extracted with DCM (2 x 1000 mL).
The combined
organic phases were dried over anhydrous Na2SO4, filtered and concentrated
under reduced pressure to
yield the subtitle compounds (-70 : 30 mixture of diastereomers) as a brown
oil (306.0 g,
1061.06 mmol, 98% yield).
LCMS: Method H3, 3.46 min, mixture of diastereomers, MS: ES+ 289.2; 1HNMR (400
MHz, CDC13)
6 ppm: 7.16 - 7.40 (m, 5H), 4.16(m, 2H), 3.91 (m, 2H), 3.65 (m, 1H), 3.49 (m,
1H), 3.32 (m, 1H), 3.18
(m, 1H), 2.92 (m, 1H), 2.64 -2.72 (m, 1H), 2.40 (s, 1H), 2.33 (m, 1H), 2.10
(m, 1H), 1.30 (t, 3H), 1.20
(d, J = 5.2 Hz, 3H); Chiral HPLC: Method Y26, 5.23 min - major peak; 5.61 min
¨ minor peak.
The method was repeated three times in an identical manner using ethyl (R)-but-
3-en-2-y1-(2-
oxoethyl)carbamate (515 g, 600 g and 760 g) to provide the subtitle compound
(respectively 751 g, 880
g and 970 g). Combined weight of all four batches: 2907 g, 10.09 mol.
Step (viii)
.. (3aR,4R,6aR)-1-Benzy1-4-methyloctahydropyrrolo[3,4-b]pyrrole, mixture with
(3aS,4R,6aS)-1-benzy1-
4-methyloctahydropyrrolo[3,4-b]pyrrole
44
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
A stirred mixture of the product of Step (vii) (-70 : 30 mixture of
diasteromers, 300.0 g, 1040.25 mmol)
in aqueous HBr (48% wt, 1988 mL 16644.12 mmol) was heated to reflux for 6 h.
The mixture was
poured into water (1.5 L, 5 vol) and washed with toluene (3 x 600 mL, 2 vol).
The aqueous layer was
basified with K2CO3 (-2.0 kg, 14563.5 mmol) up to pH -10 and extracted with
DCM (3 x 1.5 L). The
combined organic phases were dried over anhydrous Na2SO4, filtered and
concentrated under reduced
pressure. The residue was dissolved in DCM (500 mL) and thoroughly washed with
1N NaOH solution
(150 mL). The aqueous layer was extracted with DCM (200 mL). The combined
organic phases were
dried over anhydrous Na2SO4, filtered and concentrated under reduced pressure
to yield the subtitle
compounds (-70 : 30 mixture of diastereomers) as a brown oil (155.0 g, 716.49
mmol, 69% yield).
LCMS: Method F, 3.05 min, mixture of diastereomers, MS: ES+ 217.2; 1HNMR (400
MHz, CDC13)
6 ppm: 7.21 - 7.40 (m, 5H), 3.63 - 3.87 (m, 1H), 3.42 - 3.59 (m, 1H), 3.08 -
3.23 (m, 1H), 2.83 - 3.09
(m, 3H), 2.77 (m, 1H), 2.65 (s, 1H), 2.20 - 2.36 (m, 2H), 1.99 (m, 1H), 1.49
(m, 1H), 1.02 - 1.21 (m,
3H); Chiral HPLC: Method Y26, 4.98 min and 5.55 min, two discrete peaks seen
only.
The method was repeated twice in an identical manner using ethyl (3aR,4R,6aR)-
1-benzy1-4-
methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxylate (70: 30 mixture of
diastereomers, 1100 g,
and 1700 g) to provide the subtitle compounds (respectively 575 g and 838 g).
Combined weight of all
three batches: 1568 g, 7.24 mol.
Step (ix)
(3aR,4R,6aR)-1-Benzyl-4-methyloctahydropyrrolo[3,4-NpyrroleØ5 (L)-DBTA salt
To the product of Step (viii) (-70 : 30 mixture of diastereomers, 2.5 g, 11.56
mmol) was added 2.5%
water in THF (19.2 mL). A solution of (2R,3R)-2,3-bis(benzoyloxy)succinic acid
hydrate (1.28 g,
3.57 mmol, from Angene) in 2.5% water in THF (6.8 mL, 2.75 vol) was added at
rt and the solution
was stirred at rt for 2.5 h. The precipitated solid was collected by
filtration under reduced pressure and
the filter cake was washed with 2.5% water in THF (2 x 10 mL) to yield a white
solid (3.0 g).
A suspension of the white solid (3.0 g) in 2.5% water in THF (36 mL) was
heated to reflux for 1 h to
obtain a clear solution. The mixture was then allowed to cool to rt for 1 h,
then kept without stirring
for 1 h at rt. The crystallized solid was collected by filtration under
reduced pressure and the filter cake
was washed with 2.5% water in THF (2 x 10 mL) and dried under reduced pressure
at 40 C to yield
(3aR,4R,6aR)-1-benzy1-4-methyloctahydropyrrolo[3,4-blpyrroleØ5 L-DBTA as a
white solid (2.4 g,
3.03 mmol, 26% yield).
Chiral HPLC: Method Y22, 5.35 min.
Step (ix): alternative
To the product of Step (viii) (-70 : 30 mixture of diastereomers, 150.0 g,
693.38 mmol) was added
2.5% water in THF (1.2 L). The solution was seeded with (3aR,4R, 6aR)-1-
benzy1-4-
methyloctahydropyrrolo[3,4-blpyrroleØ5 (L)-DBTA salt from the previously
synthesised batch
(700 mg). A solution of (2R,3R)-2,3-bis(benzoyloxy)succinic acid hydrate
(79.50 g, 221.88 mmol,
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
from Angene) in 2.5% water in THF (412 mL, 2.75 vol) was added at room
temperature and the solution
was stirred at rt for 3 h. The reaction mixture was kept at room temperature
for 3 h. The precipitated
solid was collected by filtration under reduced pressure and the filter cake
was washed with 2.5% water
in THF (2 x 1500 mL) to yield a yellow solid (178.0 g).
.. First crystallization: A suspension of the yellow solid (178.0 g) in 2.5%
water in THF (2670 mL) was
heated to reflux for 1 h to obtain a clear solution. The mixture was then
allowed to cool to rt for 1 h,
then kept as such without stirring for 1 h at room temperature. The
crystallised solid was collected by
filtration under reduced pressure and the filter cake was washed with 2.5%
water in THF (2 x 1780 mL)
and dried under reduced pressure at 40 C to yield (3aR,4R,6aR)-1-benzy1-4-
methyloctahydropyrrolo[3,4-blpyrroleØ5 L-DBTA as a white solid (113.0 g,
142.0 mmol).
Second crystallization: The solid from the first crystallization (113.0 g) was
re-suspended in 2.5%
water in THF (1695 mL) and heated to reflux for 1 h to form a solution. The
mixture was then allowed
to cool to rt and kept as such without stirring for 1 h at room temperature.
The crystallised solid was
collected by filtration under reduced pressure and the filter cake was washed
with 2.5% water in THF
(2 x 1130 mL) and dried under reduced pressure at 40 C to yield (3aR,4R,6aR)-
1-benzy1-4-
methyloctahydropyrrolo[3,4-blpyrroleØ5 L-DBTA salt as a white solid (103.0
g, 130.22 mmol, 18%
yield).
Chiral HPLC: Method Y22, 5.31 min.
The method was repeated twice in an identical manner using (3aR,4R,6aR)-1-
benzy1-4-
methyloctahydro-pyrrolo[3,4-b]pyrrole (-70 : 30 mixture of diastereomers, 570
g and 838 g) to provide
the subtitle compound (respectively 478 g and 778 g). Combined weight of all
three batches: 1359 g,
1.72 mol.
Step (x)
tert-Butyl (3aR,4R,6aR)-1-benzy1-4-methylhexahydropyrrolo[3,4-Npyrrole-5(1H)-
carboxylate
A stirred mixture of (3aR,4R,6aR)-1-benzy1-4-methyloctahydropyrrolo43,4-
blpyrroleØ5 L-DBTA salt
(100.0 g, 126.42 mmol) in THF : water (1800 mL, 1:1.25) was heated at 50 C.
NaHCO3 (31.86 g,
379.28 mmol) was added in portions at 50 C. The mixture was cooled to 25 C,
di-tert-butyl
dicarbonate (66.14 g, 303.42 mmol) was added and the biphasic mixture was
stirred vigorously at rt for
16 h. The mixture was poured into water (500 mL) and extracted with Et0Ac (2 x
1 L). The combined
organic phases were washed with saturated aqueous NaHCO3 solution (2 x 300
mL), dried over
anhydrous Na2SO4, filtered and concentrated under reduced pressure. The
residue was purified using
column chromatography (100-200 silica gel, 20% Et0Ac in n-hexanes) to yield
tert-butyl
(3aR,4R,6aR)-1-benzy1-4-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxylate
as a grey, viscous
oil (45.0 g, 142.20 mmol, 61% yield).
LCMS: Method H3, 3.96 min, MS: ES+ 317.2; 1H NMR (400 MHz, CDC13) 6 ppm: 7.23 -
7.36 (m,
5H), 3.79 (s, 1H), 3.62 (s, 1H), 3.42 (s, 2H), 3.09 -3.14 (m, 1H), 3.02 -3.05
(m, 1H), 2.81 (s, 1H), 2.34
46
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
(s, 1H), 2.18 -2.25 (m, 1H), 1.96 -2.04 (m, 1H), 1.46 - 1.55 (m, 1H), 1.40 (s,
9H), 1.08 - 1.10 (d, J=
6.0 Hz, 3H); Chiral HPLC: Method Y23, 4.31 min, 99.6% e.e., 99.5 : 0.5 d.r.
The method was repeated twice in an identical manner using (3aR,4R,6aR)-1-
benzy1-4-
methyloctahydropyrrolo43,4-blpyrroleØ5 L-DBTA salt (200 g and 1000 g) to
provide the subtitle
compound (respectively 134 g and 685 g). Combined weight of all three batches:
864 g, 2.73 mol.
Step (xi)
tert-Butyl (3aS,4R,6aR)-4-methylhexahydropyrrolo[3,4-Npyrrole-5(1H)-
carboxylate
To a stirred mixture of tert-butyl (3aR,4R,6aR)-1-benzy1-4-
methylhexahydropyrrolo[3,4-b]pyrrole-
5(1H)-carboxylate (200.0 g, 632.01 mmol) in ethanol (1.6 L) was added 10% Pd/C
(50% moisture,
100.0 g, 0.5% w/w), then purged with H2 gas for 4 h at rt. The mixture was
filtered through a celite
Hyflow0 bed, washed with Me0H (2 x 500 mL) and concentrated under reduced
pressure to yield
tert-butyl (3aS,4R,6aR)-4-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-
carboxylate as a colourless oil
(134.0 g, 592.08 mmol, 96% yield).
LCMS: Method H3, 2.22 min, MS: ES+ 227.2; 1H NMR (400 MHz, CDC13) 6 ppm: 3.75 -
3.82 (m,
1H), 3.48 - 3.49 (m, 2H), 3.04 - 3.08 (m, 1H), 2.85 - 2.91 (m, 1H), 2.32 -
2.38 (m, 1H), 2.22 (s, 2H),
2.00 - 2.05 (m, 1H), 1.64 - 1.70 (m, 1H), 1.45 (s, 9H), 1.15 - 1.19 (d, J= 6.4
Hz, 3H); Chiral HPLC:
Method Y13, 4.55 min.
The method was repeated in an identical manner using tert-butyl (3aR,4R,6aR)-1-
benzy1-4-
methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxylate (570 g) to provide the
subtitle compound
(400 g). Combined weight of two batches: 534 g, 2.36 mol.
Example 1
(+)-(3aR*,4R*,6aR*)-1-(5-(2-Cyanopyridin-4-yl)oxazole-2-carbonyl)-4-
methylhexahydropyrrolo[3,4-Npyrrole-5(1H)-carbonitrile and
Example 2
(-)-(3aR*,4R*,6aR*)-1-(5-(2-Cyanopyridin-4-y0oxazole-2-carbonyl)-4-
methylhexahydropyrrolo[3,4-Npyrrole-5(1H)-carbonitrile
NC AN NC AN
N5AN0 0
6 1 N õ. N ,
C
N ===
N
47
CA 03186148 2022-12-05
WO 2021/249909 PCT/EP2021/065112
-Boc
,Boc
,Boc
Ng)¨fic 0 0
0 N 0 AND enantiomer -1)L
_______________________________ N __
0
AND enantiomer AND
enantiomer
NC NC TEA
m Boc 0
"
N.
(iv) \ 0, t.1H
(iii) 0
-
N N
AND enantiomer AND enantiomer
NC NC N NC
0 A 0 AN
N' N' cy N'
N /
AND enantiomer (3aS,4S,6aS) (3aR,4R,6aR)
(i) TBD, THF, 0 C to rt; (ii) m-CPBA, 0 C to rt; (iii) TMSCN,
dimethylcarbamoyl chloride, MeCN,
0 C to rt; (iv) TFA, DCM, 0 C to rt; (v) K2CO3, BrCN, THF, 0 C to rt; (vi)
chiral preparative HPLC
purification.
Step (i)
rac-tert-Butyl (3aR,4R,6aR)-4-methy1-1-(5-(pyridin-4-yl)oxazole-2-
carbonyl)hexahydropyrrolo[3,4-b]
pyrrole-5(1H)-carboxylate
To a stirred solution of ethyl 5-(pyridin-4-yl)oxazole-2-carboxylate (5.0 g,
22.93 mmol) and rac-tert-
butyl-(3aS,4R,6aR)-4-methylhexahydropyrrolo [3,4-blpyrrole-5(1H)-carboxylate
(4.15 g, 18.35 mmol)
in THF (50 mL) was added TBD (4.78 g, 34.39 mmol) in portions at 0 C. The
mixture was allowed
to warm to rt and stirred for 1 h, then poured into water (50 mL) and
extracted with Et0Ac (2 x 200 mL).
The combined organic phases were dried over anhydrous Na2SO4, filtered and
concentrated under
reduced pressure. The residue was purified by flash column chromatography
(silica gel, 2% Me0H in
DCM) to yield rac-tert-butyl (3aR,4R,6aR)-4-methy1-1-(5-(pyridin-4-yl)oxazole-
2-
carbonyl)hexahydropyrrolo [3,4-blpyrrole-5(1H)-carboxylate (5.5 g, 13.82 mmol,
60% yield).
LCMS: Method Cl, 1.14 min, MS: ES+ 399.4.
Step (ii)
rac-4-(2-((3aR,4R,6aR)-5-(tert-Butoxycarbony1)-4-methyloctahydropyrrolo[3,4-
b]pyrrole-l-
carbonyl)oxazol-5-yl)pyridine 1-oxide
To a stirred solution of rac-tert-butyl (3aR,4R,6aR)-4-methyl-1-(5-(pyridin-4-
yl)oxazole-2-carbonyl)
hexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxylate (5.5 g, 13.82 mmol) in DCM
(60 mL) was added
m-chloroperbenzoic acid (4.77 g, 27.64 mmol) in portions at 0 C. The mixture
was allowed to warm
to rt and stirred for 24 h. The reaction mixture was poured into saturated
NaHCO3 solution (200 mL)
and extracted with Et0Ac (2 x 300 mL). The combined organic phases were washed
with saturated
NaHCO3 solution (3 x 100 mL), 10% sodium thiosulfate (200 mL), dried over
Na2SO4 and concentrated
48
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
under reduced pressure to yield rac-4-(2-((3aR,4R,6aR)-5-(tert-butoxycarbony1)-
4-methyl-
octahydropyrrolo[3,4-blpyrrole-1-carbonyl)oxazol-5-yOpyridine 1-oxide (4.80 g,
11.58 mmol, 83%
yield).
LCMS: Method Cl, 1.15 min, MS: ES+ 415.6.
Step (iii)
rac-tert-Butyl (3aR,4R,6aR)-1-(5-(2-cyanopyridin-4-y0oxazole-2-carbony1)-4-
methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxylate
To a stirred solution of rac-4-(2-((3aR,4R,6aR)-5-(tert-butoxycarbony1)-4-
methyl-
octahydropyrrolo [3,4 -b] pyrrole -1-carbonyl)oxazol -5 -yOpyridine 1-oxide
(4.80 g, 11.58 mmol) in
acetonitrile (50 mL) was added dimethylcarbamoyl chloride (3.11g, 2.68 mL,
28.97 mmol) and TMSCN
(3.45 g, 34.74 mmol) dropwise at 0 C. The mixture was allowed to warm to rt
and stirred for 16 h,
then poured into water (200 mL) and extracted with Et0Ac (2 x 300 mL). The
combined organic phases
were dried over anhydrous Na2SO4, filtered and concentrated under reduced
pressure. The residue was
purified by flash column chromatography (silica gel, 2% Me0H in DCM) to yield
rac-tert-butyl
(3 aR,4R,6aR)-1-(5 -(2-cyanopyridin-4-yl)oxazole -2-carbony1)-4-
methylhexahydropyrrolo [3 ,4 -
b] pyrrole-5(1H)-carboxylate (5.1 g, 12.05 mmol, quantitative yield).
LCMS: Method Cl, 1.28 min, MS: ES+ [M+18] 441.4.
Step (iv)
rac-4-(2-((3aR,4R,6aR)-4-Methyloctahydropyrrolo[3,4-b]pyrrole-l-
carbonyl)oxazol-5-
yl)picolinonitrile
To a stirred solution of rac-tert-butyl (3aR,4R,6aR)-1-(5-(2-cyanopyridin-4-
yl)oxazole-2-carbony1)-4-
methylhexahydropyrrolo [3,4-blpyrrole-5(1H)-carboxylate (5.1 g, 2.16 mmol) in
DCM (50 mL) was
added TFA (10 mL, 2 vol) dropwise at 0 C. The mixture was allowed to warm to
rt and stirred for 2 h,
then concentrated under reduced pressure to yield rac-4-(2-((3aR,4R,6aR)-4-
methyloctahydro
pyrrolo[3,4-blpyrrole-1-carbonyl)oxazol-5-yl)picolinonitrile TFA salt (5.0 g,
11.44 mmol, 98% yield
over two steps).
LCMS: Method Cl, 0.91 min, MS: ES+ 324.3.
Step (v)
rac-(3aR,4R,6aR)-1-(5-(2-Cyanopyridin-4-yl)oxazole-2-carbony1)-4-
methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carbonitrile
To a stirred solution of rac-4-(2-((3aR,4R,6aR)-4-methyloctahydropyrrolo[3,4-
blpyrrole-1-carbonyl)
oxazol-5-yl)picolinonitrile TFA salt (0.14 g, 0.33 mmol) in THF (6 mL) was
added K2CO3 (0.14 g,
1.00 mmol) at rt and stirred for 10 min. Cyanogen bromide (0.03 g, 0.27 mmol)
was added at 0 C.
The mixture was stirred at 0 C for 15 min, then poured into water (10 mL) and
extracted with Et0Ac
(3 x 10 mL). The combined organic phases were dried over Na2SO4 and
concentrated under reduced
pressure. The residue was purified by trituration using n-pentane (2 x 10
mL) to yield
49
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
rac-(3aR,4R,6aR)-1 -(5 -(2-cyanopyridin-4-yl)oxazole-2-carbony1)-4-
methylhexahydropyrrolo [3 ,4 -b] -
pyrrole -5 (1H)-carbonitrile (0.08 g, 0.23 mmol, 88% yield, over two steps).
LCMS: Method H, 2.49 min, MS: ES+ 349.1;
NMR (400 MHz, DMSO-d6) 6 ppm: 8.89 (d, J =
4.8 Hz, 1H), 8.51 (s, 1H), 8.36 (s, 0.7H), 8.34 (s, 0.3H), 8.05 (d, J= 5.2 Hz,
1H), 5.11 - 5.19 (m, 0.4H),
4.57 -4.63 (m, 0.7H), 4.24 -4.29 (m, 0.8H), 3.89 -4.01 (m, 2H), 3.42 -3.57 (m,
2.6H), 2.51 -2.61 (m,
0.5H, obscured), 1.85 - 2.05 (m, 2H), 1.30 (d, J= 6.4 Hz, 3H), mixture of
rotamers.
The subtitle compound (1.9 g, 5.45 mmol, 47% yield) was also prepared
analogously from rac-4-(2-
((3aR,4R,6aR)-4-methyloctahydropyrrolo[3,4-blpyrrole-1-carbony1)-oxazol-5-
yOpicolinonitrile TFA
salt (5.0 g).
Step (vi)
Example 1: (+)- (3aR*, 4R*, 6aR*)-1 -(5-(2-Cyanopyridin-4-y1) oxazole-2-
carbony1)-4-
methylhexahydropyrrolo [3, 4 -b] pyrrole-5 (1H)-carbonitrile and
Example 2: (-)-(3aR*, 4R*, 6aR*)-1-(5-(2-Cyanopyridin-4-yl)oxazole-2-carbony1)-
4-
me thylhexahydropyrrolo [3, 4-b]pyrrole-5 (1H)-carbonitrile
Separation of racemate into the enantiomers Example 1 and Example 2
Each of the two enantiomers were isolated from the racemic compound rac-
(3aR,4R,6aR)-1-(5-(2-
cyanopyridin-4-y0oxazole-2-carbony1)-4-methylhexahydropyrrolo[3,4-blpyrrole-
5(1H)-carbonitrile
(1.5 g) via HPLC chromatographic separation using a Shimadzu LC-20AP
instrument coupled to a UV
detector, with a Chiralpak IC 250 mm x 21.0 mm, 5 micron column. Flow rate was
set to 20.0 mL/min.
The mobile phase was (A) 0.1% DEA in n-hexanes and (B) 0.1% DEA in 70: 30
IPA/MeCN. The UV
spectra were recorded at 295 nm lambda max. The chromatography was performed
over a 70-minute
period with isocratic mobile phase 40: 60 B/A to furnish the two enantiomers
described below, with
elution times respectively 40.0 min and 55.6 min.
Faster eluting fraction (Example 2)
(-)- (3aR*, 4R*, 6aR*)-1 -(5-(2-Cyanopyridin-4-y0oxazole-2-carb ony1)-4-
me thylhexahydropyrrolo [3, 4-b]pyrrole-5 (1H)-carb onitrile
Yield (0.44 g, 1.26 mmol), white solid.
LCMS: Method H, 2.56 min, MS: ES+ 349.2.
1H NMR (400 MHz, DMSO-d6) 6 ppm: 8.89 (d, J= 4.8 Hz, 1H), 8.51 (s, 1H), 8.35 -
8.37 (m, 1H), 8.06
- 8.07 (m, 1H), 5.12 - 5.17 (m, 0.4H), 4.59 -4.62 (m, 0.7H), 4.25 -4.29 (m,
0.7H), 3.91 -4.02 (m, 2H),
3.42 - 3.59 (m, 2.7H), 2.57 - 2.61 (m, 0.5H, obscured), 1.85 - 2.05 (m, 2H),
1.31 (d, J= 6.4 Hz, 3H),
mixture of rotamers.
Chiral HPLC: Method Yll, 12.89 min; >99% ee.
Melting point = 142 C to 146 C.
N1D25 = -208 (c = 0.05 g/100 cm', Me0H).
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
Slower eluting fraction (Example 1)
(+)-(3aR*,4R*,6aR*)-1-(5-(2-Cyanopyridin-4-yl)oxazole-2-carbony1)-4-
methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carbonitrile
Yield (0.48 g, 1.38 mmol), white solid.
LCMS: Method H, 2.56 min, MS: ES+ 349.2.
1HNMR (400 MHz, DMSO-c16) 6 ppm: 8.89 (d, J= 4.4 Hz, 1H), 8.51 (s, 1H), 8.36 -
8.38 (m, 1H), 8.06
- 8.07 (m, 1H), 5.12 - 5.16 (m, 0.4H), 4.57 -4.65 (m, 0.7H), 4.22 -4.30 (m,
0.7H), 3.91 -4.02 (m, 2H),
3.41 - 3.58 (m, 2.7H), 2.61 - 2.63 (m, 0.5H, obscured), 1.82 - 2.07 (m, 2H),
1.31 (d, J= 6.0 Hz, 3H),
mixture of rotamers.
Chiral HPLC: Method Yll, 15.09 min; >99% ee.
N1D25 = +208 (c = 0.05 g/100 cm3, Me0H).
Batch of material prepared by analogous method: Melting point = 144 C to 146
C.
Example 1 Alternative synthesis.
(+)-(3aR,4R,6aR)-1-(5-(2-Cyanopyridin-4-yl)oxazole-2-carbony1)-4-
methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carbonitrile
-Boc ,Boc ,Boc
0 0
11/ )
0 N\\. N
(i) (ii)
(iii)
NC NC NC
0 0 0
NJ/_Boo NI/ NI/ \ 0_ 6131
-
N (iv) (v) N
.p-TSA
Step (i)
tert-Butyl (3aR,4R,6aR)-4-methy1-1-(5-(pyridin-4-y0oxazole-2-
carbonyl)hexahydropyrrolo[3,4-b]
pyrrole-5(1H)-carboxylate
To a stirred mixture of ethyl 5-(pyridin-4-yl)oxazole-2-carboxylate (37.0 g,
169.72 mmol) and
tert-butyl-(3aS,4R,6aR)-4-methylhexahydropyrrolo[3,4-blpyrrole-5(1H)-
carboxylate (30.70 g,
135.64 mmol) in THF (370 mL) at 0 C was added TBD (28.32 g, 203.47 mmol) in
portions. The
mixture was allowed to warm to rt and stirred for 2 h, then poured into water
(370 mL) and extracted
with Et0Ac (2 x 370 mL). The combined organic phases were dried over anhydrous
Na2SO4, filtered
and concentrated under reduced pressure. The residue was purified by flash
column chromatography
(silica gel, 5% Me0H in DCM) to yield tert-butyl (3aR,4R,6aR)-4-methy1-1-(5-
(pyridin-4-yl)oxazole-
2-carbonyl)hexahydropyrrolo[3,4-blpyrrole-5(1H)-carboxylate as a pale yellow
solid (29.0 g,
72.78 mmol, 43% yield).
LCMS: Method H3, 2.79 min, MS: ES+ 399.2; 1H NMR (400 MHz, CDC13) 6 ppm: 8.72 -
8.82 (m,
2H), 8.20 - 8.24 (m, 1H), 7.76 - 7.77 (m, 2H), 5.10 - 5.11 (m, 1H), 4.56 (s,
1H), 4.03 (s, 1H), 3.57 - 3.85
51
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
(m, 4H), 2.09 - 2.14 (m, 1H), 1.73 - 1.86 (m, 1H), 1.36 (s, 9H), 1.21 - 1.10
(m, 3H); Chiral HPLC:
Method Y24, 5.35 min.
The method was repeated twice in an identical manner using tert-butyl-
(3aS,4R,6aR)-4-
methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxylate (165 g and 457 g) to
provide the subtitle
compound (respectively 255 g and 620 g). Combined weight of all three batches:
904 g, 2.27 mol.
Step (ii)
4-(2-((3aR,4R,6aR)-5-(tert-Butoxycarbony1)-4-methyloctahydropyrrolo[3,4-
b]pyrrole-1-
carbonyl)oxazol-5-yl)pyridine 1-oxide
To a stirred mixture of tert-butyl (3aR,4R,6aR)-4-methyl-1-(5-(pyridin-4-
yl)oxazole-2-carbonyl)
hexahydropyrrolo[3,4-b]pyrrole-5(1H)-carboxylate (29.0 g, 72.82 mmol) in DCM
(435 mL) was added
m-chloroperbenzoic acid (37.69 g, 218.46 mmol) in portions at 0 C. The
mixture was allowed to warm
to rt and stirred for 20 h, then poured into saturated NaOH solution (725 mL,
25 vol) and extracted with
DCM (2 x 290 mL). The combined organic phases were washed with 10% sodium
thiosulfate
(290 mL), dried over Na2SO4 and concentrated under reduced pressure to yield 4-
(2-((3aR,4R,6aR)-5-
(tert-butoxycarbony1)-4-methyloctahydropyrrolo[3,4-blpyrrole-1-carbonypoxazol-
5-yppyridine 1-
oxide as a yellow solid (28.30 g, 68.32 mmol, 94% yield).
LCMS: Method H3, 2.41 min, MS: ES+ 259.0 (M-56);
NMR (400 MHz, CDC13) 6 ppm: 8.25 - 8.26
(m, 2H), 8.08 - 8.11 (m, 1H), 7.78 -7.79 (m, 2H), 5.08 -5.09 (m, 0.4 H), 4.54
(m, 0.6 H), 4.02 -4.09
(m, 1H), 3.66 -3.82 (m, 4H), 2.07 -2.12 (m, 2H), 1.64-1.84 (m, 1H), 1.38 (s,
9H), 1.15 -1.19 (m, 3H);
Chiral HPLC: Method Y25, 6.13 min.
The method was repeated twice in an identical manner using tert-butyl
(3aR,4R,6aR)-4-methy1-1-(5-
(pyridin-4-yl)oxazole-2-carbonyl)hexahydropyrrolo[3,4-blpyrrole-5(1H)-
carboxylate (255 g and
620 g) to provide the subtitle compound (respectively 235 g and 550 g).
Combined weight of all three
batches: 813.3 g, 1.96 mol.
Step (iii)
tert-Butyl (3aR,4R,6aR)-1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbony1)-4-
methylhexahydropyrrolo-
[3,4-b]pyrrole-5(1H)-carboxylate
To a stirred mixture of 4-(2-((3aR,4R,6aR)-5-(tert-butoxycarbony1)-4-
methyloctahydropyrrolo[3,4-bl-
pyrrole-1-carbonyl)oxazol-5-yl)pyridine 1-oxide (28.30 g, 68.32 mmol) in
acetonitrile (1132 mL) was
added dimethylcarbamoyl chloride (22.04 g, 18.87 mL, 204.96 mmol) and TMSCN
(20.33 g,
204.96 mmol) dropwise at 0 C. The mixture was heated at 80 C for 2 h,
allowed to cool to rt and then
poured into water (280 mL) and extracted with Et0Ac (2 x 280 mL). The combined
organic phases
were dried over anhydrous Na2SO4, filtered and concentrated under reduced
pressure to yield tert-butyl
(3 aR,4R,6aR)-1-(5 -(2-cyanopyridin-4-yl)oxazole -2-carbony1)-4-
methylhexahydropyrrolo43 ,4-b1 -
pyrrole-5(1H)-carboxylate as a brown oil (28.0 g, 66.16 mmol, 97% yield).
52
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
LCMS: Method H3, 3.06 min, MS: ES+ 368.0 (M-56); IFINMR (400 MHz, DMSO-d6) 6
ppm: 8.87 -
8.88 (m, 1H), 8.48 (s, 1H), 8.34 - 8.36 (m, 1H), 8.03 - 8.05 (m, 1H), 4.55 (s,
1H), 4.02 (s, 1H), 3.55 -
3.84 (m, 3H), 2.74 (s, 2H), 2.08 - 2.13 (m, 1H), 1.75 - 1.83 (m, 1H), 1.38 (s,
9H), 1.16 - 1.20 (m, 3H);
Chiral HPLC: Method Y4, 4.67 min.
The method was repeated twice in an identical manner using 4-(2-43aR,4R,6aR)-5-
(tert-
butoxycarbony1)-4-methyloctahydropyrrolo[3,4-blpyrrole-1-carbonyl)oxazol-5-
yl)pyridine 1-oxide
(235 g and 550 g) to provide the subtitle compound (respectively 180 g and 470
g). Combined weight
of all three batches: 678 g, 1.60 mol.
Step (iv)
4-(2-((3aR,4R,6aR)-4-Methyloctahydropyrrolo[3,4-Npyrrole-l-carbonyl) oxazol-5-
yl)picolinonitrile
p-TSA salt
To a stirred mixture of tert-butyl (3aR,4R,6aR)-1-(5-(2-cyanopyridin-4-
yl)oxazole-2-carbony1)-4-
methylhexahydropyrrolo [3,4-blpyrrole-5(1H)-carboxylate (28.0 g, 66.16 mmol)
in acetonitrile
(560 mL) was added p-TSA (66.07 g, 383.72 mmol) in portions at 0 C. The
mixture was allowed to
warm to rt and stirred for 5 h, then concentrated under reduced pressure to
yield 4-(2-((3aR,4R,6aR)-4-
methyloctahydro pyrrolo[3,4-blpyrrole-1-carbonyl)oxazol-5-yl)picolinonitrile p-
TSA salt as a yellow
oil (115.0 g, quantitative yield).
LCMS: Method H3, 1.97 min, MS: ES+ 324.0; Chiral HPLC: Method Y20, 5.17 min.
The method was repeated in an identical manner using tert-butyl (3aR,4R,6aR)-1-
(5-(2-cyanopyridin-
4-yl)oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-blpyrrole-5(1H)-
carboxylate (650 g) to
provide the subtitle compound (1000 g). Combined weight of two batches: 1115
g, 3.44 mol.
Step (v)
(3aR,4R,6aR)-1-(5-(2-Cyanopyridin-4-y0oxazole-2-carbonyl)-4-
methylhexahydropyrrolo[3,4-Npyrrole-5(1H)-carbonitrile
.. To a stirred solution of 4-(2-((3aR,4R,6aR)-4-methyloctahydropyrrolo[3,4-
blpyrrole-1-carbony1)-
oxazol-5-yl)picolinonitrile p-TSA salt (180.0 g, 363.22 mmol) in THF : water
(5.4 L, 2:1) was added
K2CO3 (145.26 g, 1052.63 mmol) at rt and stirred for 5 min. Cyanogen bromide
(26.0 g, 245.61 mmol)
was added at 0 C. The mixture was allowed to warm to rt and stirred for 1 h,
then the mixture was
concentrated under reduced pressure and the residue was poured into ice cold
water (2 L) to form a
precipitate. The solid was collected by filtration under reduced pressure. The
solid was again
suspended into water (2 L) and stirred for 2 h at rt, then filtered under
reduced pressure. The solid
material was washed with cold water (1 L), followed by n-hexanes (500 mL),
diethyl ether (100 mL)
and IPA (100 mL) to yield (3aR,4R, 6aR)-1-(5-(2-cyanopyridin-4-yl)oxazole-
2-carbony1)-4-
methylhexahydropyrrolo[3, 4-blpyrrole-5(1H)-carbonitrile, (40.0 g, 114.83
mmol, 32% yield).
LCMS: Method H3, 2.50 min, MS: ES+ 349.0; 1HNMR (400 MHz, DMSO-d6) 6 ppm: 8.89
(d, J
5.2 Hz, 1H), 8.50 (s, 1H), 8.35 - 8.37 (m, 1H), 8.05 - 8.06 (m, 1H), 5.12 -
5.13 (m, 0.4H), 4.57 - 4.61
53
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
(m, 0.6H), 4.23 - 4.28 (m, 0.7H), 3.89 - 4.00 (m, 2H), 3.41 - 3.58 (m, 2.4H),
2.54 - 2.67 (m, 1H,
obscured), 1.89 -2.06 (m, 2H), 1.27 - 1.30 (m, 3H), mixture of rotamers; HPLC:
Method X2, 19.78 min,
99.96%; Chiral HPLC: Method Y15, 15.29 min; > 99% e.e.; Melting point= 147 C
to 149 C; [a]D25 =
+202 (c = 0.05 g/100cm3, Me0H).
Step (v) (alternative synthesis)
(3aR,4R,6aR)-1-(5-(2-Cyanopyridin-4-y0oxazole-2-carbonyl)-4-
methylhexahydropyrrolo[3,4-Npyrrole-5(1H)-carbonitrile
To a stirred solution of 4-(2-((3aR,4R,6aR)-4-methyloctahydropyrrolo[3,4-
blpyrrole-1-carbony1)-
oxazol-5-y1)picolinonitrilep-TSA salt (115.0 g, 232.06 mmol) in THF : water
(804 mL, 9: 5) was added
K2CO3 (98.22 g, 711.76 mmol) at rt and stirred for 10 min. Cyanogen bromide
(18.86 g, 177.94 mmol)
was added at 0 C. The mixture was allowed to warm to rt and stirred for 2 h,
then poured into water
(1150 mL) and extracted with Et0Ac (2 x 1150 mL). The combined organic phases
were dried over
Na2SO4 and concentrated under reduced pressure. The residue was suspended in
IPA (575 mL) and
heated at 80 C for 2 h to form a clear solution. The mixture was slowly
allowed to cool to rt to form a
crystalline solid, which was collected by filtration under reduced pressure,
washed with cold IPA
(115 mL) and dried under reduced pressure to yield (3aR,4R,6aR)-1-(5-(2-
cyanopyridin-4-yl)oxazole-
2-carbony1)-4-methylhexahydropyrrolo[3,4-b]-pyrrole-5(1H)-carbonitrile (15.0
g, 43.08 mmol, 19%
yield).
The method was repeated in an identical manner using 4-(2-((3aR,4R,6aR)-4-
methyl-
octahydropyrrolo[3,4-blpyrrole-l-carbony1)-oxazol-5-y1)picolinonitrile p-TSA
salt (1000 g) to provide
title compound (288 g). A solution of 288 g and 15 g of (3aR,4R,6aR)-1-(5-(2-
cyanopyridin-4-
yl)oxazole-2-carbony1)-4-methylhexahydropyrrolo [3,4-bl-pyrrole-5(1H)-
carbonitrile in THF (909 mL,
3 vol) was stirred at rt for 2 h to form a clear solution. The solvents were
removed under reduced
pressure to obtain a white solid, which was further washed with pentane (300
mL, 1 vol) and dried
under reducd pressure for 4 h at below 45 C to yield (3aR,4R,6aR)-1-(5-(2-
cyanopyridin-4-yl)oxazole-
2-carbony1)-4-methylhexahydropyrrolo[3,4-b]-pyrrole-5(1H)-carbonitrile (303.0
g).
LCMS: Method H3, 2.52 min, MS: ES+ 349.0;
NMR (400 MHz, DMSO-d6) 6 ppm: 8.87 (d, J =
3.6 Hz, 1H), 8.48 (s, 1H), 8.30 - 8.38 (m, 1H), 8.04 - 8.05 (m, 1H), 5.12 -
5.13 (m, 0.4H), 4.59 - 4.60
(m, 0.6H), 4.23 - 4.27 (m, 0.6H), 3.91 - 4.02 (m, 2H), 3.41 - 3.56 (m, 2.4H),
2.54 - 2.61 (m, 1H,
obscured), 1.84 - 2.04 (m, 2H), 1.30 (d, J= 6.4 Hz, 3H), mixture of rotamers;
Chiral HPLC: Method
Y15, 15.11 min; HPLC: Method E, 27.87 min; >99% e.e., 99.5 : 0.5 d.r.; Melting
point = 161 C to
162 C; [a]D25 = +204 (c = 0.05 g/100cm3, Me0H).
54
CA 03186148 2022-12-05
WO 2021/249909 PCT/EP2021/065112
Example 3 and Example 4
(+)-(3aR*,4S*,6aR*)-1-(5-(2-Cyanopyridin-4-yl)oxazole-2-carbony1)-4-
methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carbonitrile, and
(-)-(3aR*,4S*,6aR*)-1-(5-(2-Cyanopyridin-4-y00xaz01e-2-carb0ny1)-4-
methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carbonitrile
NC AN NC AN
0
\ 1 N 16,,,,,c,N
/ \ 0y1C-1N N / \ 0))- \,-)
µ,./- IN
N
õõ
" NH.HCI NH.HCI ¨..- ("----\ -Boc + Fraction 1 c " N-
Boc _,.. N-Boc
N' N (I) N' N',-......./ (ii)
Br Br Br / Br H
(3aR,6aR) AND (3a8,6aS) (3aR,4S,6aR) (3aR,4R,6aR)
(3aS,4S,6aR)
AND enantiomer AND enantiomer AND
enantiomer
Fraction 1 Fraction 2
1-1IN-B c ,Boc ,Boc
Ng-) _______ er 0 N 0
¨ 0--j)r-0.--- AND enantiomer / N \ 0N
0 \ IN---?'"
AND enantiomer AND
enantiomer
NC NC
N_Boc 0
_\ 0))CL
._ kit.S.,),%H .pTSA
--...... \ YL.,
(v) ' N (vi) ' N (vii)
AND enantiomer AND enantiomer
NC N NC N NC N
o A
6AN,..0, + A
N / \ a 1 61, Nb_...t0i/ N
...,... , N
\ N chiral resolution ---- "---- \ N'
AND enantiomer (3aS,4R,6aS) (3aR,4S,6aR)
Step (i)
rac-tert-Butyl-(3aR,4S,6aR)-1-benzy1-4-methylhexahydropyrrolo[3,4-b]pyrrole-
5(1H)-carboxylate
(minor isomer) and rac-tert-Butyl (3aR,4R,6aR)-1-benzy1-4-
methylhexahydropyrrolo[3,4-b]pyrrole-
5(1H)-carboxylate (major isomer)
To a stirred solution of rac-(3aR,6aR)-1-benzy1-4-methyloctahydropyrrolo[3,4-
b]pyrrole HC1 salt
((Step (v) product towards Intermediate B, 68.0 g, 269.31 mmol) in DCM (700
mL) was added
triethylamine (136.0 g, 187.3 mL, 1346.55 mmol), 4-dimethylpyridine (1.64 g,
13.46 mmol) and di-tert-
butyl dicarbonate (70.51 g, 323.17 mmol) at 0 C. The mixture was allowed to
warm to rt and stirred
for 6 h, then poured into water (1000 mL) and extracted with DCM (2 x 1000
mL). The combined
organic phases were dried over anhydrous Na2SO4 and concentrated under reduced
pressure. The
residue was purified by column chromatography (silica gel, 100-200 # size, 7
to 9% Et0Ac in
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
n-hexanes) to yield the subtitle compounds as two separate fractions, Fraction
1 (minor isomer, 0.8 g,
2.53 mmol, 0.94% yield) and Fraction 2 (major isomer, 38.0 g, 120.25 mmol, 45%
yield).
Fraction 1 LCMS: Method H1, 4.19 min, MS: ES+ 317.2. Fraction 2 LCMS: Method
H1, 3.87 min,
MS: ES+ 317Ø The minor isomer Fraction 1 was carried forward to Step (ii).
Step (ii)
rac-tert-Butyl (3aS,4S,6aR)-4-methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-
carboxylate
To a stirred solution of rac-tert-butyl-(3aR,4S,6aR)-1-benzy1-4-
methylhexahydropyrrolo[3,4-bl-
pyrrole-5(1H)-carboxylate (Fraction 1, minor isomer, 0.8 g, 2.53 mmol) in
ethanol (10 mL) was added
10% Pd/C (50% moisture, 0.8 g) and purged with hydrogen gas for 16 h at rt.
The mixture was filtered
through Celite , washed with ethanol (50 mL) and concentrated under reduced
pressure to yield
rac-tert-butyl (3aS,4S,6aR)-4-methylhexahydropyrrolo[3,4-blpyrrole-5(1H)-
carboxylate (0.42 g,
1.85 mmol, 73% yield).
LCMS: Method H1, 2.25 min, MS: ES+ 227.2.
Step (iii)
rac-tert-Butyl (3aR,4S,6aR)-4-methy1-1-(5-(pyridin-4-yl)oxazole-2-
carbonyl)hexahydropyrrolo[3,4-b]
pyrrole-5(1H)-carboxylate
A stirred solution of ethyl 5-(pyridin-4-yl)oxazole-2-carboxylate (0.49 g,
2.25 mmol) and rac-tert-butyl
(3aS,4S,6aR)-4-methylhexahydropyrrolo[3,4-blpyrrole-5(1H)-carboxylate (0.41 g,
1.79 mmol) in
toluene (7 mL) was heated at 40 C for 10 min to dissolve both starting
materials, then cooled to 0 C,
followed by addition of solution of TBD (0.15 g, 1.12 mmol) in toluene (2 mL)
dropwise at 0 C. The
mixture was allowed to warm to rt and stirred for 3 h, then poured into water
(50 mL) and extracted
with Et0Ac (2 x 50 mL). The combined organic phases were dried over anhydrous
Na2SO4, filtered
and concentrated under reduced pressure. The residue was purified by flash
column chromatography
(silica gel, 80 to 90% Et0Ac in n-hexanes) to yield rac-tert-butyl
(3aR,4S,6aR)-4-methy1-1-(5-(pyridin-
4-yl)oxazole-2-carbonyl) hexahydropyrrolo[3,4-b] pyrrole-5(1H)-carboxylate
(0.43 g, 1.09 mmol, 48%
yield).
LCMS: Method H1, 2.88 min, MS: ES+ 399.2.
Step (iv)
rac-4-(2-((3aR,4S,6aR)-5-(tert-Butoxycarbony1)-4-methyloctahydropyrrolo[3,4-
b]pyrrole-1-
carbonyl)oxazol-5-yl)pyridine 1-oxide
To a stirred solution of rac-tert-butyl (3aR, 4S, 6aR)-4-methyl-1-(5-(pyridin-
4-yl)oxazole-2-carbonyl)
hexahydropyrrolo[3,4-b] pyrrole-5(1H)-carboxylate (0.43 g, 1.08 mmol) in DCM
(7 mL) was added
m-chloroperbenzoic acid (0.37 g, 2.16 mmol) in portions at 0 C. The mixture
was allowed to warm to
rt and stirred for 16 h. The mixture was poured into water (100 mL) and
extracted with Et0Ac (2 x
100 mL). The combined organic phases were washed with saturated NaHCO3
solution (2 x 100 mL),
10% sodium thiosulfate (2 x 100 mL), dried over Na2SO4 and concentrated under
reduced pressure to
56
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
yield rac-4-(2-((3aR,4S,6aR)-5-(tert-butoxycarbony1)-4-methyloctahydropyrrolo
113 ,4 -blpyrrole -1-
carbonyl)oxazol-5-yOpyridine 1-oxide (0.39 g, 0.95 mmol, 87% yield).
LCMS: Method H1, 2.50 min, MS: ES+ [M-56] 359Ø
Step (v)
rac-tert-Butyl (3aR,4S,6aR)-1-(5-(2-cyanopyridin-4-yl)oxazole-2-carbony1)-4-
methylhexahydropyrrolo [3,4-b]pyrrole-5(1H)-carboxylate
To a stirred solution of rac-4-(2-43aR,4S,6aR)-5-(tert-butoxycarbony1)-4-
methyloctahydropyrrolo [3,4-b] pyrrole-l-carbonyl)oxazol -5 -yl)pyridine 1-
oxide (0.39 g, 0.94 mmol) in
MeCN (7 mL) was added dimethylcarbamoyl chloride (0.30 g, 0.26 mL, 2.83 mmol)
and trimethylsilyl
cyanide (0.28 g, 0.36 mL, 2.83 mmol) dropwise at rt. The mixture was heated at
80 C for 2 h, then
poured into 10% Na2CO3 solution in water (50 mL) and extracted with Et0Ac (2 x
50 mL). The
combined organic phases were dried over anhydrous Na2SO4 and concentrated
under reduced pressure.
The residue was purified by flash column chromatography (silica gel, 80 - 90%
Et0Ac in n-hexanes)
to yield rac-tert-butyl (3aR, 4S, 6aR)-1-(5 -(2-cyanopyridin-4-
yl)oxazole -2-carbony1)-4-
methylhexahydropyrrolo[3,4-bl-pyrrole-5(1H)-carboxylate (0.38 g, 0.89 mmol,
95% yield).
LCMS: Method H1, 3.15 min, MS: ES+ [M-56] 368Ø
Step (vi)
rac-4-(2-((3aR,4S,6aR)-4-Methyloctahydropyrrolo[3,4-b]pyrrole-l-
carbonyl)oxazol-5-
yl)picolinonitrile
To a stirred solution of rac-tert-butyl (3aR,4S,6aR)-1-(5-(2-cyanopyridin-4-
yl)oxazole-2-carbony1)-4-
methylhexahydropyrrolo[3,4-blpyrrole-5(1H)-carboxylate (0.38 g, 0.89 mmol) in
DCM (10 mL) was
added p-toluenesulfonic acid monohydrate (0.84 g, 4.45 mmol) in portions at 0
C. The mixture was
allowed to warm to rt and stirred for 6 h, then concentrated under reduced
pressure to yield rac-4-(2-
((3aR,4S,6aR)-4-methyloctahydropyrrolo [3,4 -b] pyrrole -1-carbonyl)oxazol-5 -
y1) picolinonitrile p-T SA
salt (0.52 g, quantitative yield).
LCMS: Method H1, 1.93 min, MS: ES+ 324Ø
Step (viii
rac-(3aR,4S,6aR)-1-(5-(2-Cyanopyridin-4-yl)oxazole-2-carbony1)-4-
methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carbonitrile
To a stirred solution of rac-4-(2-((3aR,4S,6aR)-4-methyloctahydropyrrolo[3,4-
blpyrrole-1-
carbonyl)oxazol-5-y1) picolinonitrilep-TSA salt (0.52 g, 1.01 mmol) in THF (10
mL) and water (5 mL)
was added K2CO3 (0.70 g, 5.05 mmol) at rt and stirred for 5 min. Cyanogen
bromide (0.13 g,
1.21 mmol) was added at 0 C. The mixture was allowed to warm to rt and
stirred for 1 h, then poured
into water (50 mL) and extracted with Et0Ac (2 x 50 mL). The combined organic
phases were dried
over Na2SO4 and concentrated under reduced pressure. The residue was purified
by flash column
chromatography (silica gel, 90 to 95% Et0Ac in n-hexanes) to yield rac-
(3aR,4S,6aR)-1-(5-(2-
57
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
cyanopyridin-4-y0oxazole-2-carbonyl)-4-methylhexahydropyrrolo[3,4-blpyrrole-
5(1H)-carbonitrile
(0.18 g, 0.52 mmol, 57% yield, over two steps).
LCMS: Method H1, 2.48 min, MS: ES+ 349.0; 'H NMR (400 MHz, DMSO-d6) 6 ppm 8.88
(d, J=
5.2 Hz, 1H), 8.50 (s, 1H), 8.35 (d, J= 3.6 Hz, 1H), 8.05 (dd,J= 5.2, 1.2 Hz,
1H), 5.06 - 5.10 (m, 0.6H),
4.56 - 4.60 (m, 0.7H), 4.16 - 4.21 (m, 0.7H), 3.44 - 3.95 (m, 4H), 2.81 -2.93
(m, 1H), 1.77 - 1.99 (m,
2H), 1.25 (d, J= 6.4 Hz, 3H), mixture of rotamers; HPLC: Method E, 28.58 min;
98.8: 1.2 dr.
Step
Example 3: (+)-(3aR*,4S*,6aR*)-1-(5-(2-Cyanopyridin-4-y0oxazole-2-carbony1)-4-
methylhexahydropyrrolo[3,4-b]pyrrole-5(1H)-carbonitrile, and
Example 4: (-)-(3aR*, 4S*, 6aR*)-1-(5-(2-Cyanopyridin-4-yl)oxazole-2-carbony1)-
4-
methylhexahydropyrrolo [3,4-b]pyrrole-5(1H)-carbonitrile
Each of the two enantiomers were isolated from the racemic compound rac-
(3aR,4S,6aR)-1-(5-(2-
cyanopyridin-4-y0oxazole-2-carbony1)-4-methylhexahydropyrrolo[3,4-blpyrrole-
5(1H)-carbonitrile
(0.10 g, 0.29 mmol) via chromatographic separation using a Shimadzu LC-20AP
instrument coupled
to a UV detector, with a Chiralpak IG 250 mm x 21.0 mm, 5 micron column. Flow
rate was set to
20.0 mL/min. The mobile phase was (A) 0.1% DEA in Me0H and (B) 0.1% DEA in
MeCN. The UV
spectra were recorded at 292 nm lambda max. The chromatography was performed
over a 35 minute
period with isocratic mobile phase 50 : 50 B/A to furnish the two enantiomers
described below, with
elution times respectively 8.03 min and 12.95 min.
Faster eluting fraction (Example 3)
(+)-(3aR*,4S*,6aR*)-1-(5-(2-Cyanopyridin-4-yl)oxazole-2-carbony1)-4-
methylhexahydro
pyrrolo [3, 4-b]pyrrole-5(1H)-carbonitrile
Yield (23 mg, 0.07 mmol). LCMS: Method H1, 2.49 min, MS: ES+ 349.0;
NMR (400 MHz,
DMSO-d6) 6 ppm 8.88 (d, J= 4.8 Hz, 1H), 8.50 (s, 1H), 8.35 (d, J= 3.6 Hz, 1H),
8.05 (dd, J= 5.2,
1.2 Hz, 1H), 5.06 - 5.11 (m, 0.6H), 4.56 - 4.61 (m, 0.7H), 4.16 - 4.22 (m,
0.7H), 3.43 -3.95 (m, 4H),
2.81 - 2.95 (m, 1H), 1.77 - 1.98 (m, 2H), 1.25 (d, J= 6.4 Hz, 3H), mixture of
rotamers; chiral HPLC:
Method Y17, 8.11 min.
Slower eluting fraction (Example 4)
(-)-(3aR*,4S*,6aR*)-1-(5-(2-Cyan0pyr1d1n-4-y00xaz01e-2-carb0ny1)-4-
methylhexahydropyrrolo[3,4-
b]pyrrole-5(1H)-carbonitrile
Yield (19 mg, 0.05 mmol). LCMS: Method H1, 2.49 min, MS: ES+ 349.0;
NMR (400 MHz,
DMSO-d6) 6 ppm 8.88 (d, J= 4.8 Hz, 1H), 8.50 (s, 1H), 8.35 (d, J= 3.2 Hz, 1H),
8.05 (d, J= 4.8,
1.2 Hz, 1H), 5.06 - 5.11 (m, 0.6H), 4.56 - 4.60 (m, 0.7H), 4.16 - 4.21 (m,
0.7H), 3.43 -3.95 (m, 4H),
2.81 - 2.95 (m, 1H), 1.77 - 1.99 (m, 2H), 1.25 (d, J= 6.4 Hz, 3H), mixture of
rotamers; chiral HPLC:
Method Y17, 13.17 min.
58
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
Example 3: White solid; chiral HPLC: Method Y17, 8.11 min; > 99% e.e.; 99.5 :
0.5 d.r.; melting point
= 206 C to 207 C; a1D25 = +166 (c = 0.05 g/100cm3, Me0H).
Example 4: White solid; chiral HPLC: Method Y17, 13.17 min; > 99% e.e.; 99.5 :
0.5 d.r.; melting
point = 206 C to 207 C; a1D25 = -156 (c = 0.05 g/100cm3, Me0H).
Chiral HPLC of Examples 1 to 4.
Examples 1 to 4 were analysed using HPLC and chiral HPLC methods. Baseline
separation for these
four isomers was not observed in a single system, so chiral HPLC (Method Y28)
was used to
determine the enantiomeric purity, whilst achiral HPLC (Method E) was used to
determine the
diastereomeric ratio.
Biological Activity of Compounds of the Invention
Abbreviations:
TAMRA carboxytetramethylrhodamine
PCR polymerase chain reaction
PBS phosphate buffered saline
EDTA ethylenediaminetetraacetic acid
Tris 2-amino-2-(hydroxymethyl)-1,3-propanediol
NP-40 Nonidet P-40, octylphenoxypolyethoxyethanol
BSA bovine serum albumin
PNS peripheral nervous system
BH3 Bc1-2 homology domain 3
PTEN phosphatase and tensin homologue
SDS-PAGE Sodium dodecyl sulfate polyacrylamide gel electrophoresis
DMSO Dimethyl sulfoxide
YFP Yellow fluorescent protein
VME Vinyl methyl ester
HA Hemagglutinin
Ahx Aminohexanoic acid
USP30 biochemical IC50 assay
Dilution plates were prepared at 21 times the final concentration (2100[M for
a final concentration of
100[1M) in 50% DMSO in a 96-well polypropylene V-bottom plate (Greiner
#651201). A typical
8-point dilution series would be 100, 30, 10, 3, 1, 0.3, 0.1, 0.03[M final.
Reactions were performed in
duplicate in black 384 well plates (small volume, Greiner 784076) in a final
reaction volume of 21 [11.
Either 411 of 50% DMSO or diluted compound was added to the plate. USP30
(Boston Biochem
4E582) was diluted in reaction buffer (40mM Tris, pH 7.5, 0.005% Tween 20,
0.5mg/m1 BSA, 5 mM
beta-mercaptoethanol) to achieve a final assay concentration of 4 nM, and
10[11 of diluted USP30 was
59
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
added to the compound. Enzyme and compound were incubated for 30 min at room
temp. Reactions
were initiated by the addition of 50nM of TAMRA labelled peptide linked to
ubiquitin via an iso-peptide
bond as fluorescence polarisation substrate. Reactions were read immediately
after addition of substrate
and following a 2-hour incubation at room temperature. Readings were performed
on a Pherastar Plus
(BMG Labtech). 2 Excitation 540 nm; 2 Emission 590 nm.
Activity of exemplary compounds in USP30 biochemical IC50 assay:
Example IC50 (nM)
1 11
2 1078
3 338
4 >3000
Reference Examples
Activity of exemplary compounds in USP30 biochemical IC50 assay:
Reference USP30
Structure Origin
Example IC50 (nM)
11/ H W02016/156816
A >¨ N 270
I-13c N =N Example 270
0
N-0 0 (racemate)
/ W020161156816
H3co Example 56
0
W020161156816
H3c
Example 241 72
\ ,
N z
/ 0 W02016/046530
N 310
N Example 1
JLq W02016/046530
s N
H NN 4400
Example 88
cH3
60
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
Off-Target Pharmacology
Example 1 was subject to pharmacological profiling in the Eurofins CEREP
SafetyScreen44 panel. At
a single concentration of 10 jiM, less than 50% inhibition of binding or
enzyme activity was observed
against all targets in the panel. Example 1 has a low probability for off-
target interactions due to the
low affinity for targets in this assay.
Safety Pharmacology
Example 1 was evaluated for effects on the hERG potassium channel, in stably
expressed CHO cells at
concentrations between 0.01 and 30 jt.M. Example 1 produced maximum inhibition
value of 27% of
the hERG current amplitude at 30 jiM indicating little propensity for
affecting the QT interval.
Genetic Toxicology
Example 1 was assessed in the bacterial reverse mutation assay (Ames) and in
vitro micronucleus assay.
All in vitro tests were conducted with and without exogenous metabolic
activation using concentrations
up to those limited by cytotoxicity or insolubility. Example 1 did not induce
mutations when tested up
to 5000 jig/plate with and without metabolic activation in the reverse
mutation assay in Salmonella
typhimurium strains TA98, TA100, TA1535 and TA97a and the Escherichia Coli
strain WP2 uvrA
pKM101.
Induction of chromosome damage was assessed using the in vitro micronucleus
assay in TK6 cells.
Example 1 was negative for induction of micronuclei when incubated for 3 hours
in the presence of
exogenous metabolic activation followed by 27 hours recovery, and also when
incubated for 27 hours
in the absence of exogenous metabolic activation followed by 27 hours
recovery.
TOM20-ubiquitylation assay
Human cell lines can be challenged with mitochondrial depolarizing agents
(ionophores (eg. CCCP,
valinomycin), mitochondrial complex inhibitors (oligomycin, antimycin A)) to
induce ubiquitylation of
TOM20, which is then further promoted in the presence of USP30 inhibitors.
TOM20 ubiquitylation
is subsequently assessed through western blotting of the cell lysates, with
TOM20 ubiquitylation adduct
detection possible due to an 8 kDa molecule weight increase for each molecule
of ubiquitin added,
resulting in laddering of a TOM20 immunoreactive band. TOM20-ubiquitylation
levels can be
quantified using chemiluminescence densitometry of laddered immunore active
bands.
USP30 endogenous cellular target engagement assay
Hela cells stably overexpressing YFP-Parkin were seeded into 6 well dishes.
Once adhered, cells were
treated with appropriate concentrations of test compounds or vehicle control
for 1 hour at 37 C,
5% CO2. Whole cell lysates were prepared by scraping the cells into cold PBS,
centrifuging and lysing
in lysis buffer (50 mM Tris-base, pH 7.5, 50 mM NaCl, 1% NP-40/Igepal CA-630,
2 mM MgCl2,
10% Glycerol, 5 mM beta-mercaptoethanol, cOmpleteTM mini tablets EDTA free
(Roche), PhosStop
tablets (Roche)) for 10 mins. The equivalent of 20 jtg of protein from the
cleared cell lysate was
61
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
incubated with a final cone of 2.5 [IM HA-Ahx-Ahx-Ub-VME probe at room
temperature. The reaction
was stopped by addition of 5x SDS sample loading buffer and proteins separated
by SDS PAGE and
western blotting. USP30 was detected using an anti-USP30 Sheep 5746D antibody
(MRC PPU
Reagents and Services) and a rabbit anti sheep secondary IgG (H+L) horseradish
peroxidase conjugated
(Thermo #31480) and visualised using ECL reagent (GE #RPN2109) on a GE LAS4000
imager. Target
engagement was measured by quantitation of the bands corresponding to USP30
and USP30 bound to
the Ub-VME probe and expression of this proportion compared to vehicle treated
control.
In Vitro Cytotoxicity (Cell Tox): Measured in HCT116 human colorectal
carcinoma cells using
alamarBlueTM as the assay endpoint. Compound cytotoxicity was measured over a
period of 96-hour
continual compound exposure.
Further Studies
log P: partition coefficient; lipophilicity measurement.
log D: distribution co-efficient; lipophilicity measurement.
TPSA: topological polar surface area.
Turbidimetric solubility: Test compound solution prepared in DMSO diluted into
aqueous buffer.
Turbidimetry is used as the end-point by measuring absorbance at 620 nm.
FaSSIF: simulated intestinal fluid in fasted state measured at pH 6.5.
Hep Cl mouse: in vitro hepatocyte clearance in mouse cells.
Hep Cl human: in vitro hepatocyte clearance in human cells.
Plasma The free fraction of a compound in plasma preparation determined by
in vitro equilibrium
dialysis. It is understood that only unbound (free) compound is capable of
engaging with the target.
Brain fõ,br: The free fraction of a compound in brain homogenate preparation
determined by in vitro
equilibrium dialysis. It is understood that only unbound (free) compound is
capable of engaging with
the target.
.. Cl: in vitro clearance. Cl. as defined here is the scaled clearance, in
turn calculated from the intrinsic
clearance. The intrinsic clearance is the predicted clearance due to hepatic
metabolic reactions,
determined from incubation of a compound in a hepatocyte preparation. The
lower the value in
mLiminikg, the more stable the compound.
Cl in vivo clearance: Pharmacokinetic measurement of the volume of plasma (or
any matrix) from
.. which a substance is completely removed per unit time. The lower the value
in mL/min/kg, the more
stable the compound.
Oral F: Oral Bioavailability.
MDR1-MDCK (Madin-Darby Canine Kidney cell monolayer) (in vitro) flux assay.
WT-MDCK (wild-type) in vitro flux.
Kpõõ is the ratio of unbound drug in brain to unbound drug in plasma and may
be indicative of potential
for treating peripheral and/or CNS indications.
62
CA 03186148 2022-12-05
WO 2021/249909 PCT/EP2021/065112
Studies Example 1
Cell TE WB Endogenous USP30 EC50 ([1M) 0.026
Cell Tox HCT116 EC50 (NI) >30
Log D measured at pH 7.4 1.4
TPSA 110
Physicochemical
Turbidimetric solubility ([1M) 65
FaSSIF ([1M) measured at pH 6.5 488
Hepatocyte Cl mouse scaled Cl u (mL/min/kg) 40
Hepatocyte Cl human scaled Cl u (mL/min/kg) 18
Stability Mouse plasma t1/4 (min) > 120
MDR1-MDCK Effective Efflux Ratio 3.2
WT-MDCK Efflux Ratio, A-B Papp flux (10' cm/s) 0.8, 16
Studies Example 1
Binding Mouse Plasma fu,p / Brain f
-u,br 0.14 /0.30
PK mouse 2 mg/kg IV Cl plasma (mL/min/kg) 19
PK mouse 10 mg/kg Oral F (%) 87
TOM20-Ub 1.5-f old gain Antimycin A/oligomycin mitophagy trigger 0.010
EC1.5x ( M)
Unbound plasma Cmax/TOM20-Ub cell potency (10 mg/kg PO dose - mouse) 292
Mouse Kpuu (PFCu/plasmau) 0.90
Mouse and rat PK Mouse PFCu/cell TOM20-Ub 125-fold
microdialysis Rat Kpuu (PFCu/plasmau) 0.43
30 mg/kg po Mouse PFCu >9x cell TOM20-Ub 0.5 h to > 6
h
Rat PFCu >9x cell TOM20-Ub 0.75 h to
2.25 h
Dog PK 30 mg/kg po Kpuu (CSF/plasmau) 0.41
Example 1 possesses beneficial properties demonstrating potential superiority
over other compounds.
For instance, the observed IV plasma clearance of 19 mL/min/kg, as measured in
the mouse, is low,
demonstrating valuable plasma stability, and the compound has exceptional oral
bioavailability of 87%.
Example 1 displays high CNS distribution in vivo following an oral dose, as
determined by
microdialysis sampling of brain regions following a 30 mg/kg dose in mice and
rats. High unbound
concentrations of Example 1 were observed over several hours post-dose leading
to suitable estimated
duration of target coverage in the CNS. In addition, Example 1, when dosed
orally to dogs at 30 mg/kg,
exhibited high partition to the cerebro-spinal fluid (CSF).
63
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
Ref. Ref. Ref.
Compound Ex. 1
Ex. A Ex. B Ex.
C
DUB
USP30 0.011 0.27 0.070 0.072
ICso (11M)
DUB USP2, USP6, USP10, USP16,
24.9 - 0.90 - 0.54 - 4.0 -
ICso (11M) USP21, USP25, USP28 107.2
59.4 38.8 92.4
DUB selectivity >2260 7 3.3 - 56 -
.7 - 554
preference for USP30 v 7 DUBs 220
1283
Cathepsin B 205.1 4.1 1.4 1.2
Cathepsin K 109.9 0.54 16.2
0.44
Cathepsin L 42.1 2.1 1.8 1.3
Cathepsin
ICso (11M) Cathepsin S 259.6 20.2 9.2
22.8
Cathepsin V 247.5 9.1 2.3
18.5
B K L S V > 42.1 0.54- 1.8-
0.44-
, , , ,
20.2 16.2 22.8
Selectivity preference for USP30 v cathepsins >3800 2- 75 20- 231 6.1
-317
Hepatocyte
scaled Cl u (mL/min/kg) 40 92 > 121 108
Cl mouse
Stability Mouse plasma t1/4 (min) > 120 63
21 16
Compound Ex. 1 Ref. Ex. D Ref. Ex. E
USP30 0.011 0.31 4.4
DUB 1050 ([1M)
UCHL1 > 300 0.25 6.8
DUB selectivity preference for USP30 v UCHL1 > 27000 0.8 1.5
Comparative Data
Reference Examples A, B, C, D and E are known DUB inhibitors that have been
identified as active as
inhibitors of USP30 and share some structural similarity with the compounds of
the present invention,
possessing the cyanamide structural feature. Reference Examples D and E are
disclosed in
WO 2016/046530 as having UCHL1 inhibitory activity.
Example 1 shows significantly improved hepatocyte metabolic stability (as
measured in mouse
hepatocytes) compared to Reference Examples A, B and C. Example 1 shows
significantly improved
plasma stability (at least 2 to 8-fold, as measured in mouse plasma) compared
to Reference Examples
A, B and C.
Potency for USP30
Example 1 of the present invention is significantly more potent against USP30
than Reference Examples
A, B, C, D and E, as measured in the biochemical assay. Example 1 is greater
than 6-fold more potent
than Reference Examples B and C, greater than 24-fold more potent than
Reference Examples A and
D, and 400-fold more potent than Reference Example E.
64
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
Selectivity for U5P30 over other DUBs
The data provided demonstrates that Example 1 is significantly more selective
for U5P30 over seven
DUBs (USP2, USP6, USP10, USP16, USP21, U5P25 and U5P28) compared to Reference
Examples A,
B and C. Example 1 is greater than 2260-fold more potent against USP30 than
against each of the seven
DUBs. This is a significant selectivity advantage over Reference Examples A
and B, which are as low
as 3.3-fold and 7.7-fold more potent, respectively. Reference Example C is
more selective than A and
B, but at 56-fold more potent against USP30 than against another DUB, is still
significantly inferior to
Example 1.
Selectivity for USP30 over UCHL1
The data provided demonstrates that Example 1 is significantly more selective
for USP30 over UCHL1
compared to Reference Examples D and E. Example 1 is greater than 27000-fold
more potent against
USP30 than UCHL1, whereas Reference Examples D and E are only 0.8 and 1.5-fold
more potent,
respectively.
Selectivity for USP30 over cathepsins B, K, L, S and V
The data provided demonstrates that Example 1 is significantly more selective
for USP30 over the
cathepsins (B, K, L, S and V) compared to Reference Examples A, B and C.
Example 1 is greater than
3800-fold more potent against USP30 than against each of the cathepsins. This
is a significant
selectivity advantage over Reference Examples A, B and C.
Specifically, Example 1 is greater than 18000-fold more potent against USP30
than against cathepsin
B, compared to Reference Examples B and C, which are only 20 and 16.7-fold
more potent,
respectively. Example 1 is greater than 9900-fold more potent against USP30
than against cathepsin K,
compared to Reference Examples A and C, which are only 2 and 6.1-fold more
potent, respectively.
The above-identified advantages of Example 1 of the invention over the
reference examples of the prior
art are both significant and unexpected. On their own, and in particular in
combination, this superiority
makes the compound particularly suitable for use in the treatment or
prevention of diseases linked to
USP30 activity.
Preclinical in vivo models
Compounds of the invention may be tested for efficacy in representative in
vivo disease models, using
standard study procedures from the published literature, including, for
example:
(a) Bleomycin-induced lung fibrosis model, which is a leading preclinical
in vivo model of
Idiopathic Pulmonary Fibrosis. Kobayashi et al, 2016, J Immunol, 197(2):504-
516].
(b) Diet-induced model of NAFLD and glucose homeostasis. [Nishida et al,
2013, Lab Invest;
Feb;93(2):230-411.
(c) MPTP Model of Parkinson's Disease, which is a commonly used paradigm
for looking at
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
neurodegeneration in the dopaminergic system of the brain which is triggered
by chemically-induced
mitochondrial dysfunction. [Karuppagouner et al, 2014, Sci Rep. 2014 May
2;4:48741.
(d) Ndufs4K0 Leigh syndrome model. [Kruse et al, 2008, Cell Metab.
Apr;7(4):312-20].
(e) Aged rodent model: effects on hippocampal, cognitive and motor
function. [Kobilo et al, 2014,
Learn Mem. Jan 17;21(2):119-26; Creed et al, 2019, Neuroscience. Jun
15;409:169-179; Van Skike et
al, 2020, Aging Cell. 19; e130571.
Aged rodents develop hippocampal neurodegeneration naturally, underpinning
biochemical and
functional changes in cognitive capacity. The glutamine/glutamate axis can be
taken as a surrogate for
hippocampal health given the close relationship between glutamine utilization
in neurons as part of
mitochondrial energy production.
(0 The unilateral ureteral obstructive kidney disease model (UUO).
[Chevalier et al, 2009, Kidney
Int 75(11): 1145-11521.
UUO causes renal injury characterised by tubular cell injury, interstitial
inflammation and fibrosis. It
serves as a model of irreversible post-renal acute kidney injury (AKI).
Experimental UUO has
illustrated the molecular mechanisms of apoptosis, inflammation and fibrosis,
all of which are key
processes in renal injury, regardless of the primary insult. Consequently, the
UUO model provides
investigators information beyond obstruction (Chevalier et al, 2009, Kidney
Int 75(11): 1145-1152).
Example 1 was assessed in the UUO model to determine the ability of the
compound to attenuate
progressive tubulointerstitial fibrosis and chronic kidney disease (CKD).
On day 1 of the study, adult C57BL/6 mice were dosed by oral gavage according
to one of the following
dosing regimens; Vehicle, 1.5 or 5 mg/kg Example 1 (p.o.) BID. Two hours post
dosing on day 1 study
mice underwent surgery to ligate the left ureter at two points. Successful UUO
surgery was later
confirmed by observation of dilation of renal pelvis due to hydronephrosis.
The animals were dosed
according to their prescribed regimen for 10 days at which point kidneys were
harvested, or
histopathology assessment and for protein/RNA assessment. Picrosirius Red
staining was performed
to assess the extent of collagen deposition and IHC was employed to assess
relative a-Smooth Muscle
Actin (a-SMA) expression.
Results demonstrated that both 1.5 and 5 mg/kg Example 1 (p.o.) dosed BID,
statistically reduced
collagen deposition as evidenced by reduced picrosirius red staining in
ligated kidneys. Assessment of
a-SMA staining, revealed that oral dosing of 1.5 mg/kg Example 1 BID resulted
in a statistical reduction
in a-SMA levels in UUO injured kidneys when compared to vehicle treated
controls.
(g) AKI can be induced by bilateral renal pedical clamping resulting in
ischemia reperfusion injury
ORD resulting in severe loss of renal function tubular damage and inflammation
[Lu et al. 2012.
J Nephrol. 25(5): 738-451.
66
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
Paragraphs of the invention
1. A compound of formula (I):
N ___________________________________________________ =N
N
CN
CH3
or a pharmaceutically acceptable salt thereof.
2. The compound according to paragraph 1, having the formula (IA):
>C
N
N ___________________________________________________ =N
N
(R)
CN
CH3
or a pharmaceutically acceptable salt thereof.
3. The compound according to paragraph 1, having the formula (TB):
N ___________________________________________________ =N
(R)
CN H3
or a pharmaceutically acceptable salt thereof
4. The compound according to paragraph 1, having the formula (IC):
N ___________________________________________________ =N
CN CH3
or a pharmaceutically acceptable salt thereof.
67
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
5. The compound according to paragraph 1, haying the formula (ID):
>C)
<JT
N ___________________________________________________ =N
N
(s)
CN
CH3
or a pharmaceutically acceptable salt thereof
6. The compound according to paragraph 1, which is selected from:
(3 aR,4R,6aR)-1 -(5 -(2-cyanopyridin-4-yl)oxazole -2-carbony1)-4-
methylhexahydropyrrolo [3 ,4 -
blpyrrole-5(1H)-carbonitrile;
(3 aS,4S,6aS)-1 -(5 -(2-cyanopyridin-4-yl)oxazole -2-carbony1)-4-
methylhexahydropyrrolo [3,4-
blpyrrole-5(1H)-carbonitrile;
(3 aR,4S,6aR)-1 -(5 -(2-cyanopyridin-4-yl)oxazole -2-carbony1)-4-
methylhexahydropyrrolo 113,4-
blpyrrole-5(1H)-carbonitrile;
(3 aS,4R,6aS)-1 -(5 -(2-cyanopyridin-4-yl)oxazole -2-carbony1)-4-
methylhexahydropyrrolo [3,4-
blpyrrole-5(1H)-carbonitrile;
(3 aR,4R,6aS)-1 -(5 -(2-cyanopyridin-4-yl)oxazole -2-carbony1)-4-
methylhexahydropyrrolo [3,4-
blpyrrole-5(1H)-carbonitrile;
(3 aS,4S,6aR)-1 -(5 -(2-cyanopyridin-4-yl)oxazole -2-carbony1)-4-
methylhexahydropyrrolo [3,4-
blpyrrole-5(1H)-carbonitrile;
(3 aR,4S,6aS)-1 -(5 -(2-cyanopyridin-4-yl)oxazole -2-carbony1)-4-
methylhexahydropyrrolo [3,4-
blpyrrole-5(1H)-carbonitrile; and
(3 aS,4R,6aR)-1 -(5 -(2-cyanopyridin-4-yl)oxazole -2-carbony1)-4-
methylhexahydropyrrolo 113,4-
blpyrrole-5(1H)-carbonitrile;
or a pharmaceutically acceptable salt thereof.
7. The compound according to paragraph 6, which is selected from:
(3 aR,4R,6aR)-1 -(5 -(2-cyanopyridin-4-yl)oxazole -2-carbony1)-4-
methylhexahydropyrrolo [3 ,4 -
blpyrrole-5(1H)-carbonitrile;
(3 aS,4S,6aS)-1 -(5 -(2-cyanopyridin-4-yl)oxazole -2-carbony1)-4-
methylhexahydropyrrolo [3,4-
blpyrrole-5(1H)-carbonitrile;
(3 aR,4S,6aR)-1 -(5 -(2-cyanopyridin-4-yl)oxazole -2-carbony1)-4-
methylhexahydropyrrolo [3,4-
blpyrrole-5(1H)-carbonitrile; and
(3 aS,4R,6aS)-1 -(5 -(2-cyanopyridin-4-yl)oxazole -2-carbony1)-4-
methylhexahydropyrrolo 113,4-
blpyrrole-5(1H)-carbonitrile;
or a pharmaceutically acceptable salt thereof.
68
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
8. The compound according to paragraph 7, which is:
(3 aR,4R,6aR)-1 -(5 -(2-cyanopyridin-4-yl)oxazole -2-carbonyl)-4-
methylhexahydropyrrolo [3 ,4 -
pyrrole-5(1H)-carbonitrile;
or a pharmaceutically acceptable salt thereof.
9. A compound according to any one of paragraphs 1 to 8, or a
pharmaceutically acceptable salt
thereof, for use as a medicament.
10. A compound according to any one of paragraphs 1 to 8, or a
pharmaceutically acceptable salt
thereof, for use in the treatment or prevention of a condition involving
mitochondrial dysfunction, a
cancer, or fibrosis.
11. Use of a compound according to any one of paragraphs 1 to 8, or a
pharmaceutically acceptable
salt thereof, in the manufacture of a medicament for use in the treatment or
prevention of a condition
involving mitochondrial dysfunction, a cancer, or fibrosis.
12. A method for the treatment or prevention of a condition involving
mitochondrial dysfunction,
a cancer, or fibrosis, comprising the step of administering an effective
amount of a compound according
to any one of paragraphs 1 to 8, or a pharmaceutically acceptable salt
thereof, to a patient in need
thereof
13. A compound, use, or method, according to paragraphs 10 to 12, wherein
the condition involving
mitochondrial dysfunction is selected from a CNS disorder; neurodegenerative
disease; Parkinson's
disease; Alzheimer's disease; amyotrophic lateral sclerosis; Huntington's
disease; ischemia; stroke;
dementia with Lewy bodies; frontotemporal dementia; multiple sclerosis;
mitochondrial
encephalopathy, lactic acidosis and stroke-like episodes syndrome; materially-
inherited diabetes and
deafness; Leber's hereditary optic neuropathy; neuropathy, ataxia, retinitis
pigmentosa-maternally
inherited Leigh syndrome; Danon disease; diabetes; diabetic nephropathy;
metabolic disorders; heart
failure; ischemic heart disease leading to myocardial infarction; psychiatric
diseases, schizophrenia;
multiple sulfatase deficiency; mucolipidosis II; mucolipidosis III;
mucolipidosis IV;
GM1-gangliosidosis; neuronal ceroid-lipofuscinoses; Alpers disease; Barth
syndrome; beta-oxidation
defects; carnitine-acyl-carnitine deficiency; carnitine deficiency; creatine
deficiency syndromes;
co-enzyme Q10 deficiency; complex I deficiency; complex II deficiency; complex
III deficiency;
complex IV deficiency; complex V deficiency; COX deficiency; chronic
progressive external
ophthalmoplegia syndrome; CPT I deficiency; CPT II deficiency; glutaric
aciduria type II; Kearns-
Sayre syndrome; lactic acidosis; long-chain acyl-CoA dehydrogenase deficiency;
Leigh disease or
syndrome; Leigh syndrome French Canadian variant; lethal infantile
cardiomyopathy; Luft disease;
medium-chain acyl-CoA dehydrogenase deficiency; myoclonic epilepsy and ragged-
red fiber
syndrome; mitochondrial cytopathy; mitochondrial recessive ataxia syndrome;
mitochondrial DNA
depletion syndrome; myoneurogastrointestinal disorder and encephalopathy;
Pearson syndrome;
69
CA 03186148 2022-12-05
WO 2021/249909
PCT/EP2021/065112
pyruvate dehydrogenase deficiency; pyruvate carboxylase deficiency; POLG
mutations; medium/short-
chain 3-hydroxyacyl-CoA dehydrogenase deficiency; very long-chain acyl-CoA
dehydrogenase
deficiency; peroxisomal disorders; methylmalonic acidemia; mevalonate kinase
deficiency;
age-dependent decline in cognitive function and muscle strength; and cognitive
impairment associated
with all neurodegenerative and neuropsychiatric disorders.
14. A compound, use, or method, according to paragraph 13, wherein the
neurodegenerative
disease is selected from Parkinson's disease, Alzheimer's disease, amyotrophic
lateral sclerosis,
Huntington's disease, ischemia, stroke, dementia with Lewy bodies, multiple
system atrophy,
progressive supranuclear palsy, corticobasal degeneration, frontotemporal
dementia; and Parkinson's
disease related to mutations in a-synuclein, parkin, PINK', GBA, and LRRK2,
and autosomal recessive
juvenile Parkinson's disease or early onset Parkinson's disease (EOPD), where
parkin or PINK' is
mutated, truncated or deleted.
15. A compound, use, or method, according to paragraph 13, wherein the
neurodegenerative
disease is Leigh syndrome or disease, X-linked Leigh's disease, Leigh syndrome
French Canadian
variant, and/or the symptoms associated with Leigh's disease.
16. A compound, use, or method, according to paragraphs 10 to 12, wherein
the cancer is selected
from breast, ovarian, prostate, lung, kidney, gastric, colon, testicular, head
and neck, pancreas, brain,
melanoma, bone, liver, soft tissue, cancers of tissue organs, cancers of the
blood cells, CML, AML,
mantle cell lymphoma, neuroblastoma, melanoma, soft tissue sarcoma,
liposarcoma, fibroblastic
sarcoma, leiomyosarcoma, hepatocellular carcinoma, osteosarcoma, oesophageal
cancer, leukaemia,
lymphoma, multiple myeloma, metastatic carcinoma, osteosarcoma, chondosarcoma,
Ewing's sarcoma,
nasopharyngeal carcinoma, colorectal cancer, colorectal cancer, non-small cell
lung carcinoma, cancer
where apoptotic pathways are dysregulated, and cancer where proteins of the
BCL-2 family are mutated,
or over or under expressed.
17. A compound, use, or method, according to paragraphs 10 to 12, wherein
the fibrosis is selected
from fibrosis or a fibrotic disorder associated with the accumulation of
extracellular matrix constituents
that occurs following trauma, inflammation, tissue repair, immunological
reactions, cellular
hyperplasia, and neoplasia.
18. A compound, use, or method, according to paragraphs 17, wherein the
fibrosis is selected from
fibrosis or a fibrotic disorder associated with major organ diseases,
fibroproliferative disorders, and
scarring associated with trauma.
19. A compound, use, or method, according to paragraphs 18, wherein the
fibrosis is selected from
fibrosis or a fibrotic disorder associated with interstitial lung disease,
liver cirrhosis, non-alcoholic fatty
liver disease, non-alcoholic fatty liver disease, and non-alcoholic
steatohepatitis, kidney disease, acute
kidney disease, acute kidney injury, chronic kidney disease, delayed kidney
graft function, heart or
CA 03186148 2022-12-05
WO 2021/249909 PCT/EP2021/065112
vascular disease, diseases of the eye, systemic and local scleroderma,
keloids, hypertrophic scars,
atherosclerosis, restenosis, Dupuytren's contracture, surgical complications,
chemotherapeutics drug-
induced fibrosis, radiation-induced fibrosis, accidental injury and burns,
retroperitoneal fibrosis, and
peritoneal fibrosis/peritoneal scarring.
20. A compound, use, or method, according to paragraph 19, wherein the
fibrosis associated with
interstitial lung disease is selected from sarcoidosis, silicosis, drug
reactions, infections, collagen
vascular diseases, rheumatoid arthritis, systemic sclerosis, scleroderma,
pulmonary fibrosis, idiopathic
pulmonary fibrosis, usual interstitial pneumonitis, interstitial lung disease,
cryptogenic fibrosing
alveolitis, bronchiolitis obliterans, and bronchiectasis.
21. A compound, use, or method, according to paragraph 19, wherein the
kidney disease is acute
kidney disease, acute kidney injury or chronic kidney disease.
22. A pharmaceutical composition comprising a compound according to any
one of paragraphs
1 to 8, or a pharmaceutically acceptable salt thereof, together with one or
more pharmaceutically
acceptable excipients.
23. A compound, which is selected from formulae (II), (III), (IV) and (V):
I )¨f0 0
I )'f
(C)
N NH Nr
CN (II) Cl-i3 CN (III) CH3
<ji
OZCO
N z'o
N Nc r
(Iv) cH3 cH3
or a salt of said compound; and wherein PG is a protecting group, which is
preferably selected from
tert-butyloxycarbonyl, benzyloxycarbonyl, p-methoxybenzyl carbonyl, 9-
fluorenylmethyloxycarbonyl,
acetyl, benzoyl, benzyl, carbamate, p-methoxybenzyl, 3,4-dimethoxybenzyl, p-
methoxyphenyl, tosyl,
trichloroethoxycarbonyl, 4-nitrobenzenesulfonyl and 2-nitrophenylsulfenyl.
71
CA 03186148 2022-12-05
WO 2021/249909 PCT/EP2021/065112
24. A compound according to paragraph 23, which is selected from formulae
(IA), (IIIA), (IVA)
and (VA):
.......¨N 0 1N 0
1 H
H
Z--------0 N E V"-------0
I ./..-NNH I
C6:...2 PG
N 3a N 3a
¨ =:.
ON r 1 .. s : ,
L.H3 CN 171 H3
(3aR,4R,6aR) (3aR,4R,6aR)
(ILA) (IIIA)
.........N N
0 0
1 H 1 H
V.-------0
I ::..)N\ ,--------0 N E
I N¨PG
N 3a 3a
-0
Ei
-- -_-
"
(3aR,4R,6aR) e 1 - 13 (3aR,4R,6aR) 17 1
UH3
(IVA) (VA)
or a salt of said compound.
72
